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ABSTRACT 
 
Acute pain is an important warning signal, however, neuropathic pain and often chronic pain, 
lack a physiological function. Pain is a major clinical challenge and especially chronic and 
neuropathic pain are difficult to treat. On individual level, pain causes occupational and 
functional disability, suffering, and impairs quality of life. On a macro level pain and its direct and 
indirect consequences cause multi-billion expenses. Genetic factors and mechanisms underlying 
susceptibility to chronic pain have recently raised significant scientific interest. COMT-gene, 
which codes for catechol-O-methyltransferase (COMT), is subject for genetic polymorphic 
variation and COMT polymorphisms modulate pain and opioid analgesia in humans. The effects 
of COMT on pain and opioid responses were studied in rodents and humans. In mice, COMT 
deficiency was associated with altered stress- and morphine-induced analgesia reflecting 
weakened capacity of endogenous pain modulation and changes in opioidergic transmission. In 
normal mice, COMT inhibitors reduced thresholds of mechanical nociception and shortened 
thermal nociceptive latencies and thus increased nociceptive sensitivity in models of acute and 
inflammatory pain. Pronociceptive effects were COMT-dependent. In the spinal nerve ligation 
model of neuropathic pain in rats nitecapone decreased nociceptive symptoms - cold and 
mechanical hyperalgesia and allodynia.  
 
In humans, genetic variation of COMT gene was associated with pain phenotypes. The 
associations were strongest for the experimental pain phenotypes but also clinical pain 
phenotypes, such as acute postoperative pain, showed associations (uncorrected p=0.006-0.007) 
with three single nucleotide polymorphisms (SNPs). The strongest effect was observed in the 
SNP located in the 3´UTR-region of COMT, rs887200, pointing to importance of this region in 
regulation of nociceptive phenotype and confirming the results in rodents. Together, these results 
confirm the role of COMT in pain and opioid responses. The antiallodynic effects of COMT 
inhibitors should be further studied in neuropathic pain since the safety and efficacy of current 
therapies are not satisfactory. In humans, mutations in COMT gene affect pain. The predictive 
value of individual SNPs, however, is limited and several SNPs of COMT as well as other genetic 
factors should be included in the same analysis or treatment algorithms possibly utilizing a 
haplotypic approach. Finally, the effects of most SNPs associated with pain phenotypes on 
COMT expression and activity are not known and should be explored in further studies. 
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ABBREVIATIONS 
 
Aa, amino acids 
AC, axillary clearance 
ACE, angiotensin I converting enzyme 
ANOVA, analysis of variances 
APS, haplotype with predicted low pain sensitivity  
ASIC, acid-sensing ion channel 
AUC, area under the curve 
Bp, basepairs 
CNS, central nervous system 
COMT, catechol-O-methyltransferase 
DAT, dopamine transporter 
DLPT, dorsolateral pontine tegmentum  
DNIC, diffuse noxious inhibitory controls 
DOPEGAL, 3,4-dihydroxyphenyl-glycolaldehyde 
GABA, ƣ-aminobutyric acid 
HPS, haplotype with predicted high pain sensitivity  
HUS, Hospital District of Helsinki and Uusimaa 
IL-12, interleukin 12  
i.p., intraperitoneal 
i.t., intrathecal 
i.v., intravenous 
KO, knockout mice 
L-DOPA, L-3,4-dihydroxyphenylalanine  
LITAF, lipopolysaccharide-induced TNF factor 
LPS, haplotype with predicted low pain sensitivity  
MAO, monoamine oxidase 
MB-COMT, Membrane-bound COMT 
MPE%, percentage of the maximum possible effect 
mRNA, messenger ribonucleic acid 
NAT, noradrenaline transporter 
NCF, nucleus cuneiformis 
NRS, numerical rating scale 
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PACU, post anaesthesia care unit 
PAG, periaqueductal gray 
PCA, patient-controlled analgesia device 
RVM, rostral ventromedial medulla 
s.c., subcutaneous 
SEM, standard error of the mean 
SNL, spinal nerve ligation 
SNP, single nucleotide polymorphism 
STAI, state and trait anxiety inventory 
TMD, temporomandibular joint disorder 
TNF-ơ, tumor necrosis factor alpha 
TRP, transient receptor potential channel 
UTR, untranslated region   
VAS, visual analogue scale 
WDR, wide-dynamic range neurons 
WT, wild-type mice  
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1 INTRODUCTION 
 
Pain is a sensation generated by an organism as a response to a stimulus able to cause tissue 
damage. Thus, pain has a clear evolutional value by promoting the survival of an individual. Pain, 
however, can result from damage, malfunctioning or alterations in the sensory system, and be 
present even without adequate stimulation. It is a common symptom of several pathological 
conditions and is encountered by virtually every human individual (with some exceptions) at 
some point of their lives. Severe or chronic pain can cause suffering, occupational and functional 
disability and have a devastating impact on human lives (Wall et al., 2006). Moreover, chronic 
pain is difficult to treat. This holds true especially for neuropathic pain, which is caused by a 
damage or malfunctioning of the nervous system and affects ca. 6.9-8.2% of the population 
(Bouhassira et al., 2008; Bridges et al., 2001; Costigan et al., 2009; Dieleman et al., 2008; Taylor, 
2006; Torrance et al., 2006). In neuropathic pain pharmacological therapy produces usually only a 
partial pain relief and its effectiveness is limited by several factors such as severe adverse effects 
that can exclude/prevent effective dose (Dworkin et al., 2007; Farrar et al., 2001; Finnerup et al., 
2005,2010).  
 
The pathophysiology of pain is still incompletely understood. Pain is known to have a strong 
genetic component, as genetic background affects the prevalence and intensity of symptoms of 
various painful conditions as well as the effectiveness and adverse effects of analgesics. Much 
effort has been put to the research of individual genes underlying clinical phenotypes. If such 
genes could be identified, it would offer a possibility to identify patients with increased risk of 
developing a chronic pain condition or altered response to treatment, and offer them more 
individualized treatment in an earlier stage. However, only few individual genes underlying pain 
phenotypes have been identified so far. COMT-gene, which encodes for catechol-O-
methyltransferase (COMT), is one of those that has received a significant amount of attention 
(Belfer and Segall, 2011; Kambur and Männistö, 2010; Segall et al., 2010,2012). 
 
The current works have been carried out to evaluate and characterize the significance of COMT 
in animal and human models of experimental and clinical pain.  
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2 REVIEW OF THE LITERATURE 
 
2.1 Catechol-O-methyltransferase 
 
2.1.1 Gene 
 
In humans, the COMT gene is located in chromosome 22 band q11.21 (Grossman et al., 1992; 
Winqvist et al., 1992). COMT gene contains six exons of which the first two are non-coding. The 
translation is initiated in the third exon, which contains codons for initiation of the membrane 
bound and soluble isoforms. Two separate promoters control the expression of two partially 
overlapping transcripts. The 1.5 kb transcript is expressed constitutively whereas transcription of 
the 1.3 kb specimen is regulated in tissue-specific manner (Tenhunen et al., 1993,1994; Tenhunen 
and Ulmanen, 1993). Translation of the 1.3 kb transcript results in soluble COMT (S-COMT) 
and the 1.5 kb transcript can be translated into both, membrane-bound COMT (MB-COMT) and 
S-COMT by the leaky scanning mechanism of translational initiation (Kozak, 1989; Tenhunen 
and Ulmanen, 1993).  
 
2.1.2 Protein 
 
COMT protein has at least two isoforms: soluble (S-COMT) and membrane-bound (MB-COMT) 
(Lundström et al., 1991; Salminen et al., 1990).  The isoforms differ in their expression pattern and 
in both humans and rodents S-COMT is the prevalent isoform in most of the tissues except for 
the human brain, where MB-COMT is more ( 2.5-fold) abundant than S-COMT (Hong et al., 
1998; Tenhunen et al., 1994; Tenhunen and Ulmanen, 1993). It appears that MB-COMT, 
however, can take over about 50% of the function of S-COMT, even in peripheral tissues if S-
COMT is insufficient or lacking, as in the case of S-COMT-mutant mice (Käenmäki et al., 2009). 
It has been suggested that in humans MB-COMT is present in two distinct forms, which could 
be demonstrated with enzyme-linked immunosorbent assay (ELISA) and Western blotting 
(Tunbridge et al., 2006). Even though the same band (39 kDa) of the putative MB-COMT 
12 
 
isoform has been shown also in one earlier study, it was interpreted as an artefact (Chen et al., 
2004) and the existence of the isoform has not been confirmed. 
 
In addition to S- and MB-COMT also other COMT-isoforms may exist. According to the 
ENSEMBL-database the COMT gene has 11 predicted transcripts of which 8 are protein coding, 
one mediates nonsense-mediated decay, one retains intron and one processes transcript (Table 1) 
(Ensemble database, Feb 2012). In total, 8 alternatively spliced variants of COMT protein have 
been identified (Tunbridge et al., 2007). 
 
Table 1. COMT gene transcripts.  
NAME LENGTH (bp) PROTEIN ID LENGTH (aa) BIOTYPE 
COMT-010 354 No protein product - Processed transcript 
COMT-009 546 No protein product - Retained intron 
COMT-008 724 ENSP00000387695 152 Protein coding 
COMT-005 871 ENSP00000403958 223 Protein coding 
COMT-007 1319 ENSP00000207636 199 Nonsense mediated decay 
COMT-001 1339 ENSP00000385150 271 Protein coding 
COMT-003 1457 ENSP00000384654 221 Protein coding 
COMT-002 1548 ENSP00000385917 271 Protein coding 
COMT-201 2035 ENSP00000416778 221 Protein coding 
COMT-004 2217 ENSP00000383966 235 Protein coding 
COMT-011 2437 ENSP00000354511 271 Protein coding 
Abbreviations: bp, basepairs; aa, amino acids. 
 
 
2.1.3 Distribution and function 
 
In the brain, COMT is present in glial cells and postsynaptic neurons but seems to be lacking 
from presynaptic dopaminergic neurons (Kaakkola et al., 1987; Karhunen et al., 1995a; Karhunen 
et al., 1995b; Rivett et al., 1983a; Rivett et al., 1983b). In the nociceptive system, COMT is 
expressed in superficial laminae of the dorsal horn of the spinal cord and sensory ganglia 
(Karhunen et al., 1996), as well as in supraspinal sites (Männistö and Kaakkola, 1999; Myöhänen et 
al., 2010). Cell populations expressing COMT in the spinal cord and peripheral ganglia have not 
been characterized. 
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COMT O-methylates a wide range of substrates containing a catechol structure (Axelrod et al., 
1958; Axelrod and Tomchick, 1958; Guldberg and Marsden, 1975; Nissinen et al., 1988). Its 
substrates include catecholamines dopamine, adrenaline and noradrenaline, catecholestrogens, 
drugs such as L-DOPA and other molecules carrying a catechol structure.  
 
In the brain, COMT complements presynaptic amine transporters (dopamine transporter, DAT; 
noradrenaline transporter, NAT) and monoamine oxidase (MAO) in elimination of 
catecholamines, particularly in some brain areas but their quantitative role varies in different brain 
structures (Männistö and Kaakkola, 1999). As COMT has been shown to be mainly an 
intracellular protein, it needs a mechanism to carry its substrates inside the cell, i.e. it requires 
transport such as uptake2 which transports catecholamines to glial and postsynaptic cells 
(Männistö et al., 1992; Myöhänen et al., 2010; Trendelenburg, 1990; Wilson et al., 1988). Recently 
it has been suggested that significant proportion of MB-COMT may be localised to the cell 
membrane with its catalytic domain oriented towards the extracellular side, and therefore it can 
inactivate extracellular catecholamines regardless of transport mechanisms (Chen et al., 2011a; see 
in more details below).  
 
In mice, both isoforms were expressed in all tissues in the study by Myöhänen et al. (2010). In 
comparison to peripheral tissues, expression of MB-COMT was more pronounced in the brain 
tissue, in particular in the hippocampus, in the cerebral cortical areas and the hypothalamus. Both 
isoforms were shown to be intracellular. MB-COMT was not associated with plasma membranes 
in the brain. Both isoforms were largely expressed in microglial cells, astroglial cells and intestinal 
macrophages. COMT was also expressed by some neurons, including pyramidal neurons, 
cerebellar Purkinje and granular cells and also striatal spiny neurons. It was mainly lacking from 
long projection neurons. S-COMT deficient mice also lacked nuclear COMT, which indicates the 
nuclear localization of S-COMT. 
 
In rats, it has recently been shown that in cortical neurons MB-COMT is located in cell bodies 
but also axons and dendrites (Chen et al., 2011a). It was also shown to be co-localized with 
markers of pre- and postsynaptic structures, lipid rafts and secretory vesicles. Surprisingly, C-
terminals, which contain catalytic domains of MB-COMT, were located on the extracellular side 
of the cell membrane and MB-COMT was shown to inactivate also extracellular catecholamines 
(Chen et al., 2011a).  
14 
 
 
In the striatum, the dopamine signal is primarily terminated by presynaptic uptake1 mediated by a 
DAT (Cass et al., 1993; Eisenhofer et al., 2004; Giros et al., 1996; Moron et al., 2002). DAT rapidly 
uptakes most of the released dopamine from the synapse after which it is either packed to storage 
vesicles by vesicular monoamine transporter 2 or metabolized to 3,4-dihydroxyphenylacetic acid 
(DOPAC) by MAO. Even complete lack of COMT activity in Comt knockout mice does not 
increase the extracellular dopamine level in the striatum (Huotari et al., 2002). Instead, in the 
prefrontal cortex , and some other brain areas where the density of DAT is low (Matsumoto et al., 
2003; Sesack et al., 1998), dopaminergic transmission seems to be regulated by COMT and uptake 
by the NAT (Di Chiara et al., 1992; Mazei et al., 2002; Moron et al., 2002; Mundorf et al., 2001; 
Tanda et al., 1997; Yamamoto and Nototney, 1998). In the prefrontal cortex, lack of COMT 
activity in Comt knockout mice increases dopamine levels in the extracellular fluid (Käenmäki et 
al., 2010). This was confirmed by voltametric studies, in which the elimination time of prefrontal 
dopamine was doubled (Yavich et al., 2007). 
 
COMT isoforms have functional differences. MB-COMT binds catechol substrates with much 
higher affinity than S-COMT. The reaction kinetics of these isoenzymes are different and S-
COMT has a higher enzymatic capacity (Lotta et al., 1995; Männistö and Kaakkola, 1999; Roth, 
1992). S-COMT and MB-COMT are also to some extent spatially differentially expressed 
(Myöhänen et al., 2010). On a functional level, a lack of S-COMT-activity induces neurochemical 
(Käenmäki et al., 2009) and behavioural (Tammimäki et al., 2010) effects in S-COMT mutant 
mice. In general the effects, however, are slight and occur in a sex- and tissue-dependent manner. 
After L-DOPA administration, lack of S-COMT-activity does not affect the levels of L-DOPA 
in plasma or peripheral tissues (Käenmäki et al., 2009; Tammimäki et al., 2010). When S-COMT- 
activity is lacking, MB-COMT is able to compensate about 50% of its function, even in 
peripheral tissues (Käenmäki et al., 2009). Thus, in general, S-COMT seems to play only a limited 
role in the inactivation of catecholamines whereas MB-COMT may be functionally more 
significant.  
 
Little is known about alternatively spliced variants of COMT described by Tunbridge et al. (2007). 
One variant, which is transcripted into COMT variant truncated from the C-terminal has recently 
been shown to be functionally different from normal COMT (Meloto et al., 2012). In vitro 
truncated S- and MB-COMT are less stable, but S-COMT metabolizes noradrenaline more 
efficiently, while its metabolic efficacy for catechol substrate is poorer than that of normal 
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COMT variant. Also longer COMT isoforms may exist as rs165599, which is located after the 3´ 
polyadenylation site  shown by Tenhunen et al. (1994), is present in some longer EST sequences 
in the GenBank database. mRNA species containing rs165599 have been confirmed in the brain, 
suggesting that polyadenylation sites alternative and more 3´ to the initially shown one, are being 
used (Bray et al., 2003; GenBank, http://www.ncbi.nlm.nih.gov/Genbank). 
 
Metabolic activity of COMT is subject to genetic variation of which Val108/158Met polymorphism 
is the best known (Lotta et al., 1995; Männistö and Kaakkola, 1999; Nackley et al., 2006; 
Weinshilboum and Raymond, 1977; Weinshilboum et al., 1979). According to Chen et al. (2004), 
such polymorphisms can substantially, about 40%, decrease the enzymatic activity of COMT. 
Such polymorphisms have been shown to be related to differences in physiological and 
pathophysiological processes (see below).  
 
In addition to attenuation of COMT-activity by Met-allele of Val108/158Met (rs4680), several other 
polymorphisms, described and implicated in pathological states, have been shown to modulate 
enzymatic activity of COMT in molecular, cellular, or tissue level (Bray et al., 2003; Nackley et al., 
2006; Tsao et al., 2011). Haplotypes consisting of rs4680 and synonymous SNPs located 5´ to 
rs4680 (e.g. rs4633-rs4818-rs4680) have been shown to alter secondary structure of COMT 
mRNA consequently changing its stability and efficiency of protein translation (Nackley et al., 
2006). These haplotypes have often been referred to as predicted high, average and low pain 
sensitivity haplotypes (HPS, APS and LPS, respectively), based on the studies by Diatchenko et al. 
(2005,2006). CCG-haplotype (HPS), containing rs4680G coding for valine, resulted in longest 
and most stable stem-loop structure in rs4680 proximity showing lowest rate of expression and 
enzymatic activity, as compared to other haplotypes including CGG (LPS), which also contains 
rs4680G. In the TCA-haplotype (APS), rs4818C did not reduce the level of protein expression 
but showed reduced level of COMT-activity due to the methionine coded by rs4680A. This is in 
line with the findings that also rs4633 located at the 5´ end of mRNA near the ribosomal binding 
site modulates protein expression in vitro. Its T-allele which is APS haplotype-specific increases 
translational efficiency and protein expression in tissue-specific manner, in some tissues to the 
level of LPS or even higher (Tsao et al., 2011). Also SNPs rs737865 located in the first intron of 
the MB-COMT transcript and rs165599 modulate expression of COMT mRNA via cis-acting 
mechanisms at least in the brain tissues (Bray et al., 2003). Rs737865 C-allele is associated with 
decreased allelic expression of rs4633C-rs4680G transcripts. The effect is likely brain/CNS-
specific and not mirrored by gross changes in peripheral COMT activity, as rs737865 is located 
16 
 
within the first intron of the MB-COMT, which contributes little to the peripheral COMT 
activity. As to rs165599, variants containing G-allele show lower relative expression and are 
overrepresented in schizophrenic patients. The mechanism of these effects and possible role of 
alternatively spliced variants remain to be investigated (Bray et al., 2003; GenBank, 
http://www.ncbi.nlm.nih.gov/Genbank).  
 
 
2.1.4 COMT inhibitors 
 
COMT-inhibition. Nitecapone, OR-486 and other COMT-inhibitors (Fig. 1) decrease COMT 
activity in the peripheral tissues and to some extent in the CNS. In behavioural animal studies, a 
COMT-inhibitor dose of 30 mg/kg has been generally used (Diatchenko et al., 2005; Nackley et 
al., 2007). At this dose, both nitecapone and OR-486 selectively, specifically and strongly inhibit 
COMT (Nissinen et al., 1988). Duration of action of nitecapone is ca. 3 hrs (III), while that of 
OR-486 is longer and some of the newer compounds can inhibit COMT activity even for 24 hrs 
(Nissinen et al., 1988; Nissinen and Männistö, 2010). OR-486 and, to some extent, nitecapone, 
penetrate the blood-brain barrier and lead to a temporary inhibition of COMT in the brain 
(Nissinen et al., 1988; Nissinen and Männistö, 2010) (III). 
 
OTHER EFFECTS. Nitrocatechol-structured inhibitors of COMT, such as nitecapone, are 
also potent antioxidants. Nitecapone scavenges reactive oxygen species and nitric oxide radicals 
and prevents lipid peroxidation (Männistö and Kaakola, 1999; Marcocci et al., 1994a,b; Nissinen et 
al., 1995; Suzuki et al., 1992). As antioxidative effects occur already at clinically relevant 
concentrations, they can at least partially attribute to the beneficial effects of COMT in some 
pathological states. In a rat model of diabetes, nitecapone improves various symptoms such as 
kidney function (Pertovaara et al., 2001). It also exhibits a protective effect on gastric lesions 
which lasts longer than 6 hrs, and the concomitant stimulatory effect on the release of 
prostaglandin E2 can last more than 12 hrs (Aho and Lindén, 1992). 
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Fig.1. Chemical structures of dopamine and COMT inhibitors used in pain studies. 
 
OTHER USES, ANIMALS. Tolcapone, but also entacapone, have beneficial effects in animal 
models of depression (forced swimming test and learned helplessness paradigm) when combined 
with L-DOPA (Männistö et al., 1995). However, in another animal model of depression (chronic 
mild stress-induced anhedonia), also tolcapone alone has alleviated depressive behaviour (Moreau 
et al., 1994). The effects of COMT inhibitors on learning and memory have also been studied. 
Tolcapone has been shown to improve working and spatial memory performance in animal 
models, but the effect was slight and test-specific (Khromova et al., 1997; Liljequist et al., 1997). 
Tolcapone also improved executive memory processes in rats (Lapish et al., 2009). 
 
CLINICAL USE. Peripheral COMT inhibitors are increasingly used in the treatment of 
Parkinson’s disease as adjuncts to L-DOPA therapy that mainly alleviates motor symptoms. 
COMT inhibitors protect a significant amount of L-DOPA from metabolism, thus prolonging its 
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action and allowing a reduction of its doses (Männistö and Kaakkola, 1999). In patients suffering 
from Parkinson’s disease entacapone increases the mean "on" time and correspondingly reduces 
the time, frequency and severity of the "off" periods time (Mizuno et al., 2007; Pellicano et al., 
2009; Rinne et al., 1998). Entacapone increases the availability of L-DOPA increasing its effect by 
1/3, which allows reduction of required daily L-DOPA dose (Rinne et al., 1998). Symptoms were 
rapidly improved in 69% of patients receiving also entacapone, and the effect was sustained until 
the end of the study (Larsen et al., 2003). Moreover, positive therapeutic effects have been shown 
in elderly Parkinson patients with more severe symptoms and experiencing L-DOPA related 
wearing-off effect (Pellicano et al., 2009). When compared with dopaminergic agonists, 
entacapone was also more effective than cabergoline showing quicker onset of therapeutic effect 
in conjunction with L-DOPA (Deuschl et al., 2007). Entacapone also provides additional 
therapeutic value in patients receiving dopaminergic agonist therapy (Fenelon et al., 2003). 
Entacapone is well tolerated and during a 3-year follow-up study, only 14% of the patients 
discontinued the treatment due to adverse effects (Larsen et al., 2003). Its main adverse events 
include diarrhoea, insomnia, dizziness, nausea, increased dyskinesias, urine discoloration, 
aggravated parkinsonism, and hallucinations (Larsen et al., 2003; Mizuno et al., 2007; Rinne et al., 
1998). Increase of dopaminergic adverse events, mainly dyskinesias, occurred mostly in the 
beginning of the treatment and could be alleviated by reducing the L-DOPA dose (Larsen et al., 
2003; Rinne et al., 1998). 
 
Other COMT inhibitors, tolcapone (Ebersbach and Storch, 2009; Factor et al., 2001; Koller et al., 
2001) and nibecapone (Ferreira et al., 2010) have been similarly effective in treating symptoms of 
Parkinson’s disease when combined with L-DOPA. Tolcapone has shown more pronounced 
therapeutic effect while having similar tolerability. However, it has potentially severe hepatic 
adverse effects, which have limited its use (Borges, 2003,2005; Ebersbach and Storch, 2009; 
Factor et al., 2001). 
 
In addition to L-DOPA adjunct therapy, several other indications have been suggested for 
tolcapone. In clinical settings it has been studied in a small open study in major depressive 
disorder patients (Fava et al., 1999). It was found to be effective, but its use has not gain 
popularity due to adverse effects, and a lack of properly conducted double-blinded randomized 
studies (Fava et al., 1999). Tolcapone has also been shown to improve cognition and cortical 
information processing in healthy human subjects (Apud et al., 2007) and parkinsonian patients 
 
   19 
 
(Gasparini et al., 1997), and has been suggested to improve cognitive deficits associated with 
schizophrenia (Apud and Weinberger, 2007). However, these indications remain disputed. 
 
 
 
2.2 Nociception and pain 
 
2.2.1 Nociception in the periphery and primary nociceptors 
 
Stimuli of intensity high enough to potentially cause tissue damage, are initially detected by 
primary sensory nociceptive neurons, which can be categorized into two different types, AG- and 
C-fibers (Fig. 2) (Albrecht and Rice, 2010; Reichling and Levine, 1999; Wall et al., 2006). Axons 
of AG-fibers are thicker than C-fibers and they are myelinated resulting in higher conduction 
velocity of action potentials. The cell bodies of these first neurons are located in dorsal root 
ganglia or trigeminal root. First neurons are unipolar and the distal branches of their axons 
terminate at the surface of the skin, joints, muscle tissue, or viscera. The second branch of the 
axon enters the spinal cord or, in case of trigeminal nerves, the brainstem at the level of the pons. 
 
FUNCTION. Stimuli of different modalities such as heat, mechanical, acid etc., applied to the 
peripheral endings of primary nociceptors, activate specialized proteins, such as ion channels of 
transient receptor potential channel (TRP) or acid-sensing ion channel (ASIC) family (Nilius and 
Owsianik, 2011; Wemmie et al., 2013). Activation leads to excitatory ion currents that cause 
depolarization of the nerve ending and generation of action potentials. Action potentials are then 
propagated by voltage-gated ion channels along the axon to the CNS. 
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Fig. 2. Nociception in the periphery and spinal cord. 
 
 
The functional state of nociceptive neurons varies and not all of the nociceptive neurons are active. 
Many of them remain in an inactive “silent” state under physiological conditions, but, for example 
during inflammation, they can become activated by chemical messengers, such as hormones and 
neurotransmitters. 
 
PRIMARY NOCIREPTORS. Primary nociceptors are a heterogeneous group of sensory afferent 
neurons, which respond to nociceptive stimulation (Cain et al., 2001; Perl, 1996). Primary nociceptors 
can be grossly classified to C-fibers and A-fibers. Whereas some nociceptors are specialized, most of 
them are polymodal and respond to different types of stimuli. Both types of nociceptors are usually 
described as mechano-heat sensitive, but most also respond to chemical stimulation. So-called “silent 
nociceptors” (30% of C-fibers and 50% of A-fibers) are functionally more passive and mechanically 
insensitive. They either do not respond or have very high threshold (>60 g/mm2) to mechanical 
stimulation. Some of the silent nociceptors, however, respond to chemical stimulation.  
 
 
2.2.2 Nociception in the spinal cord 
 
Spinal cord receives inputs from primary nociceptors, other primary afferents carrying information 
from the periphery, and descending projections from the brain (Todd, 2010; Wall et al., 2006). Primary 
nociceptors originating from skin, muscle, joints, and viscera terminate and arborize at different 
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laminae of the dorsal horn. The connection pattern is highly organized and it depends on the type of 
afferent fibers and the modality of their receptive fields. Thinly myelinated and slow fibers represent 
the majority of nociceptors and synapse at superficial layers of the dorsal horn. Primary nociceptors 
make synaptic connections with several types of neurons. They synapse with projection neurons 
ascending anteriorly to various brain regions (1) and axons of projection neurons (posteriorly) 
descending from different brain regions that modulate processing of nociceptive information at the 
spinal level (2). First-order nociceptors also synapse with   interneurons (3), whose axons remain within 
the spinal cord in the same segment or project to other segments, and terminals of other primary 
sensory afferents that supply non-nociceptive information to the spinal cord (4). Primary nociceptors 
also make functional connections directly and indirectly with other neuronal and non-neuronal 
components of the spinal cord (5). These include neurons of autonomous and motor nervous system 
and glial cells, which mediate various responses to nociceptive stimulation but are also involved in 
modulation of nociception. 
 
Primary nociceptors make excitatory glutamatergic synapses with projection neurons, thus providing 
flow of nociceptive information to the brain (Todd, 2010; Wall et al., 2006). Also, synaptic connections 
of primary nociceptor terminals and interneurons, are mostly excitatory. However, a large variety of 
other neurotransmitters are used in spinal synapses. Interneurons can be divided according to their 
function into excitatory interneurons releasing glutamate, and inhibitory interneurons releasing ƣ-
aminobutyric acid (GABA) or glycine. Both types of interneurons have various integrative and 
modulatory functions and are important processors of nociceptive information in physiological and 
pathological states. For example, discharges of tactile afferents can activate nociceptive neurons, which 
under normal circumstances are suppressed by inhibitory interneurons. Suppression can be blocked by 
spinal administration of GABA-A or glycine antagonists leading to tactile allodynia. The malfunctioning 
of the inhibitory interneurons is one of the underlying factors of clinical tactile allodynia. 
 
 
2.2.3 Inflammation, nerve injury, and modulation of spinal and peripheral 
nociception 
 
MODULATION OF PERIPHERAL NOCICEPTION. Primary nociceptors are highly dynamic 
entities whose structure and function integrate changes in their environment, which are reflected in 
their action (Basbaum et al., 2009; Wall et al., 2006). Environment can modulate primary nociceptors by 
different mechanisms and involve for example, inflammatory processes. Tissue injury, which often 
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accompanies trauma or other pathological states, can cause inflammation which modulates the 
properties and function of primary nociceptors contributing to pain and hyperalgesia (Basbaum et al., 
2009; Linhart et al., 2003; Petho and Reeh, 2012; Schumacher 2010; Uçeyler et al., 2009; Verri et al., 
2006). During inflammation, immune and other cells release various inflammatory mediators, such as 
arachidonic acid metabolites, bradykinin, ATP, NO and other small molecules, inflammatory cytokines 
and chemokines, growth factors, and also classical neurotransmitters such as noradrenaline. 
Inflammatory mediators act on peripheral terminals of nociceptive neurons. Several types of polymodal 
nociceptors express inflammatory mediator receptors, including G-protein coupled receptors, ligand-
gated ion-channels, cytokine receptors and receptor tyrosine kinases. Activation of these receptors 
activates different second messenger cascades, which alter molecular and structural properties of 
primary nociceptors via phosphorylation, methylation, changes in gene expression, and other 
mechanisms. Changes in structural and molecular properties of primary nociceptors can activate and 
sensitize nociceptive terminals and change their response properties. They can decrease the activation 
threshold to stimuli of one or several modalities, and increase responsiveness to suprathreshold 
stimulation. Altered functional properties of primary nociceptors are critical in several chronic pain 
states. 
 
Inflammation can also affect the spinal nociceptive system by releasing the same inflammatory 
mediators in the spinal cord, or indirectly via altered discharge activity of primary nociceptors and 
consequent release of neurotransmitters in the spinal cord (Linley et al., 2010). 
 
MODULATION OF SPINAL NOCICEPTIVE FUNCTIONS. Spinal neuroplastic changes can 
cause various sensory and other consequences including clinically significant symptoms, such as 
secondary hyperalgesia and tactile allodynia. In the spinal cord, different types of primary afferents are 
synaptically connected with second order nociceptive neurons and other cells. They release a variety of 
chemicals, which mediate transmission of nociceptive information to other spinal and supraspinal 
structures. Connections also mediate different spinal responses including motor and autonomic 
responses. Connections are highly organized and topographically distinguishable. However, they are 
also extremely dynamic. Increased or altered activity of primary nociceptors is followed by changes in 
the amount or composition of chemical substrates they release. Chemicals can be released by other 
spinal cells but also by peripheral tissues in synaptic or paracrine manner. Peripheral substrates can 
access the spinal cord by crossing blood-cerebrospinal fluid-barrier utilizing different transport 
mechanisms or disruption of the barrier caused by trauma or other pathologies. Chemicals activate 
whole plethora of receptors and secondary messenger cascades in other cells. This causes changes in 
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intracellular milieu of target cells, modulates intracellular components, regulates gene expression, and 
modulates the activity of other cells (e.g. glial cells). These activity-dependent neuroplastic changes 
temporarily or permanently alter processing of nociceptive information and other functions of spinal 
cells. For example, repetitive stimuli of constant intensity applied on C-fibers causes pattern of action 
potentials which lead to progressive, frequency-dependent facilitation of the responses of wide-dynamic 
range neurons (WDR) which is referred as wind-up (for review, see Coste et al., 2008; Herrero et al., 
2000). 
 
NERVE INJURY. Neuropathic pain has been defined as “pain initiated or caused by primary lesion 
or dysfunction of nervous system”, or more recently as “pain arising as a direct consequence of a lesion 
or disease affecting the somatosensory system” (Merskey and Bogduk, 1994; Treede et al., 2008). 
Clinical manifestation of neuropathic pain consists of a well characterized and defined set of clinical 
symptoms which can arise from numerous pathological states and involves different pathobiological 
mechanisms. Neuropathic pain affects ca. 6.9-8.2 % of the population and it can be caused by several 
factors such as trauma, viral infections, chemotherapy, or metabolic disorders that lead to damage or 
malfunctioning of the nervous system (Bouhassira et al., 2008; Bridges et al., 2001; Costigan et al., 2009; 
Davis, 2007; Dieleman et al., 2008; Taylor, 2006; Torrance et al., 2006; Zimmermann, 2001). 
Neuropathic pain manifests as spontaneous burning pain in the absence of stimuli, sensitization to both 
noxious stimuli (hyperalgesia), pain sensation caused by innocuous stimuli of different modalities 
(allodynia), and other sensory symptoms (Costigan et al., 2009; Jensen and Finnerup, 2007; Woolf and 
Mannion, 1999). 
 
Transition from nerve injury to neuropathic pain is not self-evident. Nerve injury leads to clinical 
neuropathic pain symptoms only in a fraction of patients. Prevalence of the symptoms varies greatly 
and depends on different factors including location, type, and extent of damage to the nervous system 
and type and size of the damaged nerves. Also, age and gender of the patient, genetic and epigenetic 
factors play a role. Moreover, acute nociceptive symptoms elicited by the injury and their treatment and 
emotional and cognitive factors affect the occurrence of neuropathic pain symptoms (Costigan et al., 
2009). 
 
Neuropathic pain can involve different pathophysiological mechanisms, the importance of which 
varies between different neuropathic pain conditions, underlying factors and phase of the disease 
(Bridges et al., 2001; Costigan et al., 2009). Mechanisms include peripheral sensitization, ectopic impulse 
generation and transduction, recruitment of low-threshold AƢ-fiber to nociceptive transmission, central 
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sensitization, disinhibition of nociceptive neurons and structural changes. Plastic changes can be 
detected upstream in the spinal cord and even in the brain even if damaged nerve(s) would be in the 
periphery (Zimmermann, 2001). As pathophysiology of neuropathic pain may involve different 
mechanisms, several drugs affecting different ion channels or neurotransmitter systems are used and 
have shown efficacy in its treatment (Cruccu, 2007). Drugs acting through different mechanisms are 
often co-administered to achieve adequate pain relief (Dworkin et al., 2007). However, neuropathic pain 
is often difficult to treat, as pharmacological therapy produces usually only partial pain relief, and 
adverse effects are often intolerable preventing optimal dosing (Costigan et al., 2009; Farrar et al., 2001). 
 
 
2.2.4  From nociception to pain – the role of the brain  
 
FROM SPINAL CORD TO THE BRAIN. A subpopulation of neurons of the spinal cord projects 
to the brain supplying it with sensorimotor information. Groups of projection neurons originating 
from the same area of the spinal cord, and directly or indirectly, connecting it to the same brain region 
have been conceptualized as ascending nociceptive tracts. Consequently, ascending nociceptive tracts 
can be classified or named according to the brain regions where projection neurons terminate. 
Spinothalamic tract connects the spinal cord with several thalamic regions (Fig. 3) and is the main 
nociceptive tract, whereas spinobulbar tract connects with the brainstem, and spinohypothalamic with 
the hypothalamic region. Also other tracts have been named (e.g. spinoreticular, spinocervical, 
spinoparabrachial and spinoamygdalar tracts and postsynaptic dorsal column pathway), but their 
classification and nomenclature are not unambiguous and may vary among different sources (Wall et al., 
2006; Willis, 2007). It must be noted that despite anatomical resemblance and close location, the 
neurons originating from the same area of the spinal cord can be differentially regulated, project to 
different sites, and serve different purposes.  
 
Regardless of the tract, the neurons carrying nociceptive information originate mostly from superficial 
(lamina I) layers of the dorsal horn, but also from deeper (laminae IV-V) layers, from the intermediate 
zone and medial ventral horn (laminae VII-VIII) (spinothalamic tract and other) (Fig. 3). Axons of 
projection neurons cross the spinal cord and ascend contralaterally or bilaterally, depending on the 
brain area they target. Axons of projection neurons of spinothalamic tract ascend mainly in lateral or 
anterior funiculus.  
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Fig. 3. Spinal ascending nociceptive projections. In the figure, spinal origin and route of lateral and anterior 
spinothalamic tracts are highlighted with green and orange colours, respectively. 
 
 
In the brain, the projection neurons terminate in thalamic, spinobulbar, or hypothalamic regions, which 
provide different types of nociceptive responses. Thalamus is the main gateway of nociceptive and 
other sensory information, and spinal projections terminating here process the greatest part of 
ascending nociceptive information and contribute to the largest part of final pain experience. 
Spinothalamic cells terminate in different regions of the thalamus e.g. ventral medial nucleus, ventral 
caudal part of the medial dorsal nucleus and ventral posterior nucleus, which process and further 
transfer the nociceptive information to other brain regions. In the spinobulbar projections, axons target 
the regions of catecholamine cell groups (A1-A7; incl. locus caeruleus, A6), parabrachial nucleus, 
periaqueductal gray (PAG) and reticular formation of the brain stem. In these areas, the nociceptive 
information is integrated with the homeostatic processes and processes regulating the behavioural state. 
Nociceptive information is further transferred to forebrain and is also used to modulate neuronal 
activity at spinal and forebrain levels, which can modulate pain experience. Hypothalamic projections 
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could be involved in autonomic, neuroendocrine, and emotional dimensions of nociception, but 
understanding their role, especially in primates and humans, requires further studies. 
 
FROM NOCICEPTION TO PAIN – processing in different brain areas. From the thalamus, 
nociceptive information is further propagated to other brain structures modulating their function. Brain 
areas activated by nociceptive stimulation can be visualised and studied by in vivo imaging techniques, 
and are often referred to as the pain matrix. Activation of different brain regions can be seen after 
application of experimental pain stimuli (Shenoy et al., 2011) in different pain conditions, such as 
fibromyalgia (Gracely and Ambrose, 2011) or neuropathic pain (Chen et al., 2008), but also in other 
pathological conditions in which pain symptoms are present, such as in Parkinson’s disease (Stoessl, 
2009). Some of the brain activation may result from other stimuli such as the activation of 
somatosensory cortex by touch, or other situational factors. However, nociceptive stimulation also 
induces brain activation, which is nociception-specific and can be distinguished from other signals 
(Chen et al., 2011b; Chen et al., 2012). Activation patterns of anterior cingulate cortex, prefrontal cortex, 
primary and secondary somatosensory cortices, insular cortex, amygdala, thalamus and PAG are 
relatively consistent (Chen et al., 2008; Wall et al., 2006). Across the studies, however, there is some 
variation and activation patterns may depend on the modality and duration of stimuli, experimental or 
underlying pathological conditions and patient group.  
 
WHAT DOES THE BRAIN ACTIVATION MEAN OR CAN TELL US? Activation of the 
brain area can reflect its involvement in processing of nociception. Activation of certain parts of 
nociceptive circuitry can cause pain. For example, electrical stimulation of medial parietal operculum or 
posterior insula, can cause pain in the absence of nociceptive stimulation (Mazzola et al., 2011). Even 
though activation of other brain areas does not cause pain, they may be required for more coordinated 
activation or be crucial for some aspects of pain. Correspondingly, attenuation of processing in some of 
nociceptive brain areas by means of stimulation, such as transcranial magnetic stimulation, or 
neurosurgery can in some cases alleviate pain symptoms and is sometimes used as a treatment in 
otherwise intractable pain (Wall et al., 2006).  
 
Functionally, brain areas activated by nociceptive stimuli are neurophysiological correlates of the 
subjective psychological pain experience. They integrate nociceptive input with other internal and 
external information, giving the pain its dimensions – aspects, finally resulting in wholesome pain 
experience. From neuropsychological perspective, the experience of pain can be conceptualized into 
sensory-discriminative and affective-motivational components. Sensory-discriminative component 
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encompasses localization of the stimuli, discrimination of its intensity and quality.  Affective-
motivational component contributes to negative hedonic quality and emotional reaction, general 
activation or arousal, stimulus selective attention, the drive to terminate the stimulus causing the 
sensation, leading to withdrawal or verbal reaction (Treede et al., 1999). Additionally, a cognitive 
component could be considered to be an entity on its own. 
 
Pain is processed by brain areas and networks that also have other psychological or neurological 
functions. In addition to pain, activated brain areas can often process other types of stimuli or other 
types of emotional, cognitive, motivational etc. information. The brain area coding for location and 
intensity of tactile stimulation, for example, could process both innocuous and noxious touch, and the 
area coding for unpleasantness of pain could also be activated in other unpleasant experiences. Thus 
nociceptive brain circuitry is partially shared and overlapping with other brain processes. If nociceptive 
and other brain functions co-occur and are processed simultaneously, simultaneous processing can 
interfere with pain (Chan et al., 2012; Legrain et al., 2005, 2012; Lorenz and Garcia-Larrea, 2003; 
Seminowicz and Davis, 2007). Such interference or modulation can be caused by expectation, 
distraction, emotional context, cognitive, situational or other factors and attenuate pain if it recruits 
processing networks and decrease resources required/reserved for nociceptive processes. This has been 
utilised by different mind-body therapies but also some of the actions of analgesic drugs can be partially 
explained by their effects on these brain areas (Bushnell et al., 2013). Modulation, however, is not 
inevitably inhibitory but can also be facilitatory and increase pain. Nociceptive circuits can, at least 
partially, also be activated in the absence of nociceptive stimulation, for example when images of pain 
are being shown or memorized (Shimo et al., 2011).  
 
The degree and extent of activation of neural nociceptive networks by noxious or innocuous stimuli 
vary and is shaped by current and earlier pain experiences (Bushnell et al., 2013). Activation may be 
more pronounced or recruit wider brain circuitry in chronic pain patients (Shimo et al., 2011). Thus, 
brain does not only integrate and process nociceptive information, but is also shaped by nociceptive 
information. Chronic pain can alter neuronal connections of the brain and cause structural changes and 
reorganization, which can be seen by imaging techniques in clinical pain states (Henry et al., 2011). Such 
changes can be maladaptive and strengthening of nociceptive connections can increase severity of the 
pain symptoms. Plasticity of the brain, on the other hand, can be utilized in the clinic: amount of non-
pain-related information received and processed by the brain can be increased by for example 
sensorimotor training, which reduces and even reverses structural changes and pain symptoms 
(Napadow et al., 2012).  
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DOWNSTREAM MODULATION OF PAIN. Although the experience of pain is shaped by co-
occurring cerebral processes, the main mechanism of pain modulation remains downstream regulation 
of nociceptive input (Tracey and Mantyh, 2007). Modulation of ascending nociceptive transmission is 
carried out by a descending projection network including frontal lobe, anterior cingulate cortex, insula, 
amygdala, hypothalamus, PAG, nucleus cuneiformis (NCF), dorsolateral pontine tegmentum (DLPT) 
and rostral ventromedial medulla (RVM) (Fig. 4) (Ossipov et al., 2010; Tracey and Mantyh, 2007). One 
of the best described and the most important neural circuits is the PAG region of the midbrain, which 
is connected to the RVM projecting to the spinal cord. PAG receives inputs from several cortical and 
other brain areas including rostral anterior cingulate cortex, hypothalamus and amygdala. PAG projects 
to the RVM. RVM is formed by nucleus raphe magnus, nucleus reticularis gigantocellularis and some 
other brain areas, and it projects to spinal and medullary dorsal horns. This circuit directly and 
indirectly modulates transmission and processing of nociceptive information flowing from the 
periphery by altering characteristics of electrical impulse trails ascending to the brain, thus altering 
nociceptive input received by the brain. 
 
Downstream regulation is crucial from the clinical perspective: regulatory networks are involved in 
endogenous modulation of pain and are mediating the therapeutic effects of several pharmacological 
and non-pharmacological treatments. The dysfunction of these networks can manifest as clinical pain 
states or undermine pain therapies by reducing their efficacy or by causing side effects. Modulation of 
nociception can be inhibitory or facilitatory (Tracey and Mantyh, 2007). Both types of modulation have 
several functional, evolutional, pharmacological and clinical implications. Both systems seem to be 
simultaneously active and functioning, feeding and regulating each other. Thus, the resulting 
nociceptive status of the organism is dynamic and determined by functional status of both of these 
systems.  
 
INHIBITORY MODULATION. Descending inhibition of pain is involved in a naturally activated 
control system, namely conditioned pain modulation (in earlier literature referred to as diffuse noxious 
inhibitory controls, DNIC) (Yarnitsky, 2010), whereby the response of WDR neurons in the dorsal 
horn (for review, see Le Bars, 2002) and trigeminal nuclei (Dallel et al., 1999) to C-fibre activation is 
inhibited by the application of noxious stimuli to remote body areas. Descending inhibition of pain can 
also occur after exposure to environmental stressors, which modulate nociceptive responses in animals 
(Yamada and Nabeshima, 1995). Modulation is stressor- and modality-specific and can involve different 
neurotransmitter systems (Lapo et al., 2003; Lewis et al., 1980; Mitchell et al., 1998; Mogil et al., 1996; 
Yamada and Nabeshima, 1995), and it has been used in different pain studies as a scientific tool. Some 
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stressors (such as 3 min swim in 32°C water) activate the endogenous opioid system inhibiting 
nociceptive responses for a short period of time, which can be prevented by administration of naloxone 
(Lapo et al., 2003; Lewis et al., 1980; Mitchell et al., 1998; Mogil et al., 1996; Yamada and Nabeshima, 
1995).  
 
FACILITATORY MODULATION. Activation of certain brain areas and pathways can facilitate the 
nociceptive transmission (McNally, 1999). Facilitation involves different anatomical structures and 
relies on inhibition of neurons of endogenous analgesic circuits or direct facilitation of neurons of 
ascending nociceptive tracts. Facilitatory circuits can be classified based on several factors, and from 
nociceptive and functional point of view, facilitatory circuits can be antianalgesic, inhibiting analgesia, 
or hyperalgesic, increasing basal pain sensitivity. Antianalgesic and hyperalgesic components can co-
occur but also be present independently from each other. 
 
 
2.3 COMT and nociception: animal studies 
 
Effects of COMT on nociception have been characterized in a few experimental animal studies 
using COMT inhibitors or mice with modified Comt gene. COMT inhibitors are pronociceptive 
in models of acute and inflammatory pain in rodents and the effects have been shown in 
different modalities of nociceptive stimuli (Diatchenko et al., 2005; Nackley et al., 2007).  The 
effects were blocked by administration of adrenergic Ƣ2/3 inhibitors. In models of neuropathic 
pain, however, nitecapone and OR-486 have shown profound antiallodynic and antihyperalgesic 
properties in behavioural and electrophysiological experiments (Jacobsen et al., 2010; Pertovaara 
et al., 2001; for details, see Kambur and Männistö, 2010). A first generation COMT inhibitor, 
tropolone, has also caused lethal interactions with morphine, but such effect should rather be 
attributed to the non-specific effects of tropolone that are lacking from more specific and 
selective COMT inhibitors (Davis et al., 1979a,b) (Kambur and Männistö, 2009, unpublished data).   
 
In COMT gene modified mice, overexpression of a high-activity COMT variant decreases 
nociceptive sensitivity, whereas knockout of COMT increased pain sensitivity (Papaleo et al., 
2008; Walsh et al., 2010). Also a lack of S-COMT induced subtle sex-dependent changes of 
nociceptive phenotype suggesting different roles for COMT isoforms, which is in line with their 
expression pattern and effects on catecholamine metabolism (Tammimäki et al., 2010).  An 
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extensive study comparing genotypic differences with gene expression in a genome-wide analysis 
of 29 inbred mouse strains proved that genomic variation affect expression of Comt1 which is cis-
regulated and mainly determined by insertion of SINE-element in the 3´ untranslated region 
(UTR) (Segall et al., 2010). SINE-insertion increased expression and activity of Comt1 by about 
20%, which was verified in transfected cell line, and the increase in COMT activity was 
accompanied by reduced nociceptive sensitivity. Expression of Comt mRNA and COMT activity 
in inbred mouse strains (C57 and DBA) have also been shown to correlate with morphine 
responses (Grice et al., 2007). 
 
 
2.4 Effect of genetic variation in COMT gene on human pain 
 
2.4.1 Experimental pain 
 
Val108/158Met. There are several human studies assessing the association of genetic 
polymorphisms in COMT gene and pain. The most studied is the common SNP rs4680, often 
referred to as Val108/158Met. In SNP rs4680 a non-synonymous change of G to A occurs, resulting 
in a replacement of valine by methionine at codon 158. Such replacement increases thermolability 
of the enzyme and decreases COMT activity (Lotta et al., 1995; Männistö and Kaakkola, 1999). 
The effect of this polymorphism on pain was first suggested by Zubieta et al. (2003) in a small 
and ethnically heterogeneous cohort (Zubieta et al., 2003). Pain was caused by injection of 
hypertonic saline to the masseter muscle and the amount of saline needed to achieve a predefined 
pain level was used as an indicator of pain sensitivity. Homozygous Met/Met (A/A) carriers were 
the most sensitive, whereas volunteers lacking the A-allele (G/G, Val/Val carriers) were the least 
sensitive, and the heterozygotes (A/G, Val/Met) showed intermediate pain sensitivity. 
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Fig. 4. Descending modulation of pain.  In the figure, main parts of descending modulatory pathways are 
highlighted with orange colour. PAG - periaqueductal gray, NCF - nucleus cuneiformis, RVM - rostral ventromedial 
medulla, DLPT - dorsolateral pontine tegmentum.  
 
Several other studies using different nociceptive models and patient/volunteer samples, however, 
failed to show an association between SNP rs4680 and experimental pain caused by nociceptive 
stimulation of different modality and/or duration (Birklein et al., 2008; Diatchenko et al., 
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2005,2006; Jensen et al., 2009; Kim et al., 2004a; Potvin et al., 2009). In a large cohort of healthy 
females, Val108/158Met genotype was associated with the rate of temporal summation of heat pain, 
but neither with other pain measures (pressure pain threshold, threshold and tolerance of thermal 
and ischemic pain), nor with summed pain scores (Diatchenko et al., 2005, 2006). In another 
study, SNP rs4680 affected the cold pain threshold when the effect of the confounding SNP in 
gene coding for FAAH (rs4141964 causing T>C) was taken into account, and carriers of the 
variant COMT genotype (Val/Val) were less sensitive to cold pain than non-carriers (Met/Met) 
(Lötsch et al., 2009a). However, if the confounding genotype was not taken into account, the 
results lost their significance. Thus, it seems that SNP rs4680 may affect pain as assessed in 
different experimental pain paradigms involving hypertonic saline, temporal summation of the 
heat pain or sensitivity to cold pain. The effect of COMT genotype, however, has varied among 
different studies and seems to be prone to confounding effects of other genetic factors (Lötsch et 
al., 2009a) or other determinants of pain such as psychological phenotype (George et al., 2008a), 
gender (Kim et al., 2006b) which should be paid attention at and included in data analysis. 
 
OTHER SNPs and HAPLOTYPES. In addition to rs4680, the effect of five other SNPs in 
the COMT gene (rs2097903, rs6269, rs4633, rs4818, rs165599) and their combination haplotypes 
on pressure, thermal and ischemic pain and temporal summation of thermal pain have been 
evaluated in the same cohort (Diatchenko et al., 2005, 2006). The SNPs rs6269 and rs4818 were 
associated with pain ratings accounting for 6% (rs6269) and 7% (rs4818) of variation in the pain 
sensitivity. The effect of haplotypes on pain sensitivity was greater than that of any individual 
SNP. Three major haplotypes constructed in the study encompassed 96% of the genetic variation 
in the COMT gene and determined COMT activity that correlated with pain sensitivity. A high 
COMT activity was associated with a low sensitivity to pain and vice versa, and a correlation was 
first shown when pain was assessed by Z-scores, which are a combined outcome measure 
incorporating pressure pain thresholds, thermal pain thresholds and tolerance, temporal 
summation of thermal pain, ischemic pain threshold and tolerance (Diatchenko et al., 2005). 
Among the individual pain measures, the associations were strongest for the threshold and 
tolerance of the thermal pain whereas other nociceptive variables showed the same trend, while 
lacking statistical significance (Diatchenko et al., 2006). The rate of temporal summation of heat 
pain (which was associated with the Val108/158Met genotype) did not differ between haplotype 
combinations. Thus it seems, that the Val108/158Met SNP while contributing for variation in a 
temporal summation of pain and some other nociceptive variables, is less significant than other 
SNPs or haplotypes of COMT gene, which are more important determinants of a resting 
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nociceptive sensitivity. Also in another study a low COMT-activity haplotype (constructed using 
SNPs rs4633 and rs4818) was associated with an increased intensity of acute experimental muscle 
pain (but had no effect on other secondary outcomes including a muscle torque production and a 
self-report of upper-extremity disability) as assessed by visual analogue scale (VAS) (George et al., 
2008a). The effect was seen in volunteers with high pain catastrophising scores, suggesting an 
interaction between COMT gene and psychological phenotype. Finally, in a study assessing the 
effects of 13 COMT SNPs (rs5746846, rs2020917, rs933271, rs5993882, rs740603, rs4646312, 
rs165722, rs6269, rs4633, rs4818, rs4680, rs174699, rs165728) in a large (n=735) cohort of 
healthy volunteers, SNPs rs4646312 and rs6269 were associated with cold pain sensitivity. The 
effect was gender specific and seen exclusively in females (Kim et al., 2006b). 
 
2.4.2 Clinical pain  
 
The effect of genetic variation in COMT on clinical pain has been evaluated by numerous studies 
in patients with diagnosed clinical, mostly chronic pain conditions using different approaches.  
These studies have assessed the prevalence of different COMT variants in different patient 
groups, risk of developing chronic pain condition or pain symptoms in different genotypes or 
impact of variants on pain symptoms. 
 
CHRONIC PAIN STUDIES. There are many studies evaluating the effect of COMT on 
symptoms in different chronic pain conditions (for references, see Kambur and Männistö, 2010; 
Tammimäki and Männistö, 2012). In several conditions, such as temporomandibular joint 
disorder (TMD), fibromyalgia, migraine or headache, COMT genotype seems to play a role, since 
variants with a low predicted COMT activity can increase their incidence or symptoms. At least 
in TMD, pronociceptive effect of a low COMT activity genotype was reversed by propranolol, a 
non-selective ß-receptor antagonist, supporting involvement of adrenergic ß2/3-receptors in 
mechanism of pronociceptive effects (Tchivileva et al., 2010). Variation in COMT seems to 
modulate not only pain intensity, but also other aspects of pain conditions. COMT genotype may 
contribute to psychological consequences of pain. For example, in fibromyalgia pain induced 
more pronounced attenuation of positive mood in Met/Met-carriers  (Finan et al., 2010). Also 
other symptoms of pain conditions, such as fatigue, disability, and morning stiffness in 
fibromyalgia (Vargas-Alarcon et al., 2007) as well as nausea and vomiting in migraine attacks (Park 
et al., 2007), can be modulated by COMT. In general Met/Met-genotype has been associated with 
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more severe symptoms. In some of the chronic pain conditions, such as in neuropathic or cancer 
pain, the evidence for the modulatory role of COMT is lacking.  
 
There is a significant variation among chronic pain studies evaluating the effect of COMT 
variants and some of the studies failed to replicate the effect of COMT, especially in smaller 
cohorts or more heterogenic patient groups. Unfortunately, the vast majority of such studies fail 
to report estimates of their statistical power, making it difficult to evaluate if these studies were 
even capable of detecting the gene effect. This also suggests that for reliable evaluation of gene-
effects in future studies, more attention should be paid to sufficient cohort size, control for 
confounding variables and overall quality of studies. It must be noted that the effect of COMT on 
pain is not only dependent on the pain condition, but also on psychological factors, ethnic 
background  and sex which can interact with the gene effect or act as independent confounders 
(Fijal et al., 2010; George et al., 2006a,b; Slade et al., 2007; Vargas-Alarcon et al., 2007). Failure to 
account for such factors may explain lack of significance in some of the studies.  
 
ACUTE PAIN STUDIES. There are only few studies assessing the effect of COMT genotype 
on acute pain. COMT has been reported to modulate pain symptoms in arthroscopic, 
orthopaedic, cardiac, and oral surgery patients (Ahlers et al., 2013; Henker et al., 2013; Mamie et 
al., 2013; for review, see Kambur and Männistö, 2010). Rs4633-rs4818 haplotypes with low 
COMT activity were associated with higher pre- and postoperative pain in arthroscopic surgery 
patients, and the effect was modulated by psychological phenotype (high pain catastrophising 
scores) (George et al., 2008b). In postoperative pain ratings after oral surgery, surprisingly, SNP 
rs740603 showed the strongest effect and A/A-carriers were less sensitive and had lower pain 
ratings, even though the association was weak (Kim et al., 2006a). In orthopaedic, abdominal and 
cardiac surgery patients, rs4680A (Met) was associated with higher pain ratings (Ahlers et al., 
2013; Henker et al., 2013; Mamie et al., 2013). Similarly, GCGG-haplotype containing rs4680 has 
been associated with postoperative pain (Henker et al., 2013). In some pain conditions, the effect 
of COMT variation may be at least partially reversible by adrenergic Ƣ-receptor blockade, since 
propranolol reduced the composite pain index in TMD patients with a low COMT activity 
haplotype in gene-dependent manner (Tchivileva et al., 2010).  
 
Compared with experimental pain, acute clinical pain is much more variable. In a clinical setting, 
pain is caused by inflammation, injury, or surgery which vary in their extent, location and stage. 
Consequently, origin and intensity of nociceptive stimuli vary. Since they both correlate with pain 
intensity, they are important sources of variation. The pain, underlying pathology, and 
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comorbidities are always treated due to ethical and legislative reasons. Treatment can also 
interfere with intensity of pain and represents another major source of variation. Pain 
measurements themselves can be important confounders, as patients are often assessed, due to 
practical reasons, at different time points, in differing conditions, and by different personnel. 
Intensity of acute pain is most reliably assessed in a standardized manner (such as VAS or NRS) 
and directly, since it is less prone to confounding factors than indirect measures. Pain is also a 
subjective measure and, therefore, anchors of NRS and VAS-scales (worst imaginable pain) are 
by no means objective. Controlling for confounders usually requires a prospective study design 
allowing uniform inclusion criteria, more homogenous cohorts, and standardised measurement 
protocols. This is laborious, which has led to small sample sizes in most of the studies assessing 
effect of COMT on acute clinical pain. However, despite of small sample sizes and higher amount 
of variation, several studies have shown association between acute clinical pain and genetic 
polymorphisms in COMT (Ahlers et al., 2013; George et al., 2008b; Henker et al., 2013; Kim et al., 
2006a; Mamie et al., 2013).  
 
 
2.4.3 Conclusions from human studies  
 
Several studies on chronic and acute pain show a significant effect of genetic variation in COMT 
on pain. The effect seems to depend on phenotype as seen from results of chronic pain studies 
suggesting differential role of COMT in different pain conditions, which is logical considering 
heterogeneity of pain pathologies. Also, the role of catecholamines and other factors are 
phenotype-dependent. Effect of COMT may depend on genotype, as seen from different results 
from different SNPs and haplotypes. Especially assessment and interpretation of effects of 
individual SNPs seems problematic. First of all, existing data indicate limited explanatory value of 
each individual SNPs alone. A vast majority of the studies assessed Val108/158Met, leaving variation 
in the rest of the gene completely unaddressed. Val108/158Met, despite being extensively 
characterized and having confirmed molecular mechanism of action, is not the only determinant 
of COMT function. Also, several other SNPs play a role, and have been shown to be more 
important than Val108/158Met in several acute and chronic pain studies. If their effect is not taken 
into account in statistical analyses, they can act as confounders undermining the results, and 
leading to unjustified conclusions.  What comes to other COMT SNPs, their effects have been 
assessed only in a tiny fraction of studies and in most of them, their effects on COMT activity 
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have not been verified. Also other SNPs except Val108/158Met, are not sole determinants of 
COMT function. Their effect depends on other SNPs, which form their immediate environment 
together with other genetic machinery (see below). Thus, the effects of multiple putatively 
effective SNPs have to be addressed simultaneously. Such an assessment is, however, difficult 
from statistical point of view. 
 
From statistical perspective, several clinical pain studies assessing multiple SNPs showed 
significant associations. However, when multiple hypotheses are tested the risk of type I error 
and false positives increases. Since type I error is generally considered important, it is typically 
addressed by correction for multiple comparisons. Such corrections, however, decrease statistical 
power. Indeed, in studies assessing COMT SNPs and clinical pain some of the effects did not 
reach the level of statistical significance after corrections. Corrections for multiple comparisons 
increase type II error, which in the case of COMT SNPs would mean a lack of statistically 
significant association when the effect of SNP on pain phenotype is real. Whereas type I error 
has often been addressed, type II error has been grossly overlooked and appropriate power 
analysis, describing detection limits and sensitivity of used statistical approach, are mostly non-
existent. As in the case of COMT, its effects have often been shown in other pain studies or even 
seen in the same study in different phenotypes thus addressing the risk of type I error and getting 
positive association due to random variation, such approach seems overconservative.  
 
Evaluating COMT haplotypes appears to be the best way to assess the effect of COMT on pain 
and take into account multiple COMT SNPs. Several acute and chronic studies showed that low 
COMT-activity haplotypes increase pain, supporting involvement of COMT. Finally, the effect 
may also depend on non-genetic confounding factors, which need to be taken into account in 
both, chronic and acute pain studies.  
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2.4.4 COMT genotype and effect of opioids 
 
In several studies, COMT genotype has been shown to affect opioid responses in experimental 
and clinical settings. In general, genetic variants with a low COMT activity enhance opioid 
analgesia but also adverse effects, at least in cancer and postoperative pain patients (see Kambur 
and Männistö, 2010 for detailed description; Henker et al., 2013; Jensen et al., 2009; Matsuoka et 
al., 2012; Rakvåg et al., 2005, 2008; Reyes-Gibby et al., 2007; Ross et al., 2008; Zubieta et al., 2003). 
The effects are also seen in genetic variants whose effect on COMT activity is not known. 
Finally, effects of COMT on opioid analgesia and adverse effects are modulated by 
polymorphisms in other genes. In analgesic effect, interaction was reported with polymorphism 
in OPRM1-gene (Reyes-Gibby et al., 2007), whereas in adverse effects interaction was seen with 
multidrug-resistance1 gene (Ross et al., 2008). Thus, gene-gene interactions need to be taken into 
account in further studies addressing effects of COMT on opioid responses. Finally, the 
modulatory effect of COMT has mostly been shown in cancer pain patients treated with 
morphine. Despite of that, it could be speculated that COMT would similarly modulate the 
effects of other μ-receptor agonists, as well as other patient groups. In future studies, however, 
one could expect that in heterogeneous patient groups (such as Lötsch et al., 2009b) where 
intrinsic non-genetic variation is high, sample size must be increased to get statistically significant 
results.  In accordance with this, in a recent multicenter study, COMT SNPs rs4680 and 
rs4646312 were associated with differences in the median opioid dose in cancer patients 
(Klepstad et al., 2011). Differences were significant in a large sample despite heterogeneity in 
pathology of cancer, nociceptive symptoms, opioid medication, and other issues. However, the 
differences did not reach the level of statistical significance in a smaller validation sample.  
Besides analgesia, COMT genotype may modulate other effects of morphine as well, such as 
central adverse effects (Ross et al., 2008). Genotype affected “central adverse effects” as well as 
“drowsiness and confusion or hallucinations”, especially in patients with moderate or severe 
symptoms. Significant associations were seen in haplotype 1, which is present in 10% of the 
population, and in SNPs in intron 1 which defines the haplotype. SNP rs740603 showed the 
strongest association with the protective effect, and G-carriers were less likely to have adverse 
effects than non-carriers. Also T-allele of SNP rs174680 showed a weak association. Effect of 
COMT genotype was modified by a SNP rs2032582 (Ala893Ser/Thr) in multidrug resistance-1 
gene (G-allele). COMT genotype did not affect other, non-CNS-mediated, adverse effects or 
cognitive status (Rakvåg et al., 2008; Ross et al., 2008).  
38 
 
3 AIMS OF THE STUDY 
 
 
The general aim was to study the role of COMT in pain using Comt gene modified animals and 
COMT inhibitors in experimental models of pain, and to study the clinical relevance of COMT 
polymorphisms in human pain in a large cohort of patients who were exposed to experimental 
and postoperative pain and genotyped for the COMT gene. 
 
 
 
MODULATION OF NOCICEPTION AND PAIN BY COMT  
 
The specific aims were:  
 
1.  To characterize the effects of an inborn COMT deficiency on experimental acute 
nociception and opioid responses in mice.  
 
2. To measure the effects of COMT inhibitors on experimental acute and inflammatory pain 
in normal mice. 
 
3. To find out whether nitecapone has antinociceptive effects in neuropathic pain in rats. 
 
4. To study the effect of genetic variation in COMT gene on experimental and clinical 
postoperative pain in patients scheduled for breast cancer surgery. This includes 
assessment of COMT SNPs and haplotypes in experimental pain, acute postoperative 
pain and opioid requirements. 
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4 MATERIALS AND MAIN 
METHODS 
 
 
4.1 Animal and biochemical experiments 
 
4.1.1 General 
 
MICE. Male Comt gene disrupted mice were used in studies I and II. Comt gene disrupted 
animals were originally generated by Gogos et al. (1998). In the study I homozygous mice (full 
Comt knockout mice), heterozygous mice and their wild-type littermates, aged 8–10 months at the 
beginning of the experiments, were used (I). Also in the study II 25 Comt knockout mice (for a 
detailed description of these mice, see Tammimäki et al., 2008) were used in the behavioural 
experiments (II). 
 
Mice were bred in the National Laboratory Animal Center (Kuopio, Finland), breeding 
heterozygous males and females produced by regularly enriching the homozygous animals with 
C57BL/6J mice (I). The mice were genotyped using Southern blotting as described in Huotari et 
al. (2002) (I). The Comt deficient mice show no gross phenotypes, compared to the wild-type 
mice (Gogos et al., 1998; Huotari et al., 2002). They breed normally, their lifespan is normal and 
they have normal diurnal rhythm (Gogos et al., 1998; Haasio et al., 2003). 
 
In addition, in the study II a total of 196 male wild-type mice of the C57BL/6J background 
(Harlan, Horst, the Netherlands), aged 3–4 months and weighing 26–34 g were used. 
 
RATS. Rats were used in studies II and III. Intrathecal infusions were done in 15 adult male 
Wistar rats (Harlan, Horst, the Netherlands) weighing 200–300 g (II). In the study III eighty-six 
male Wistar rats, (Harlan Laboratories, Horst, The Netherlands) weighing 140–350 g in the 
beginning of the experiment were used (14 in a pilot experiment, 48 in the behavioural tests and 
24 specifically in the COMT activity measurements). The Wistar strain was chosen to allow 
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comparison of the results with the earlier diabetes model study (Pertovaara et al., 2001). Rats of 
this strain have been reported to develop neuropathic pain symptoms after the spinal nerve 
ligation (SNL) model of neuropathic pain (Lee et al., 1997; Lovell et al., 2000), which was also 
verified in a pilot experiment in our own laboratory. Animals were randomly allocated to 
treatment groups so that in each cage the number of animals assigned to each treatment group 
was approximately equal. 
 
HOUSING. The animals were housed in group cages in groups of 3-4 (III). To allow recovery 
after the SNL surgery the animals were transferred to single cages and returned to home cages 2–
4 days after the surgery. In other studies the animals were housed in individual cages (I and II) at 
an ambient temperature of 21–24°C (I, 21–23°C; II and III, 22–24°C). Artificial lighting 
followed a fixed 12-hr light-dark cycle (I, II and III). All experiments were conducted during the 
light phase of the day (I, II and III). All animals had free and continuous access to food pellets 
and drinking fluid (tap water) which were available ad libitum (I, II and III). 
 
SELECTION and HABITUATION. The animals were not pre-selected for nociceptive or 
behavioural experiments (I, II and III). After the surgery (II and III), however, only the animals 
in which surgery was successful/showing appropriate clinical/behavioural phenotype were used 
in nociceptive measurements. The animals were habituated to the testing environment and 
handling for 2-4 consequent days before the experiments (I and II, 4 days; III, 2-4 days). The 
animals spent 10–30 min in each of the testing apparatus (except the tail flick) and the order of 
habituation was the same as the testing order during experiments (I, II and III). Rats were also 
habituated again during the experiment to each test setting for 15 min before the actual 
measurements (II and III). 
 
 
4.1.2 Nociceptive measurements in rodents 
 
Nociceptive measurements in mice (I and II) and rats (II and III) included assessment of 
latencies of thermal nociception (I and II) with hot plate, tail flick and paw flick tests, 
measurement of mechanical nociceptive thresholds (II and III) and cold allodynia responses 
(III). 
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HOT PLATE TEST (Eddy and Leimbach, 1953; Le Bars et al., 2001; O’Callaghan and 
Holzman, 1975; Woolfe and Mac-Donald, 1944) (Harvard Apparatus, Kent, UK) was applied in 
both mice (I and II) and rats (II) in identical manner. Briefly, the animal was placed on the top of 
the hot plate covered by plexiglass cylinder (diameter) within which it was allowed to move freely. 
The temperature in the hot plate was 52 ± 0.2 °C. When the first nociceptive behaviour, either a 
withdrawal and brisk shaking or licking of the hind paw or jumping, occurred the animal was 
removed from the test and the latency to response was recorded. To prevent tissue damage, a 60 
s cut-off time was used (I and II). 
 
TAIL FLICK TEST (Hardy, 1953; Hardy et al., 1957; Le Bars et al., 2001) was applied in studies 
I and II (model DS20, Ugo Basile, Comerio, Italy). The mouse was gently restrained by wrapping 
in the soft towel and its tail was placed in the device on the top of the photocell. The device 
produced infrared radiant light (100 W bulb, 15 V) which was focused on the tail skin by 
parabolic aluminium mirror. The intensity of the light beam was set to 50 arbitrary units what in 
average produced a response in 2–3 s in pilot experiment (I and II). When the animal withdrew 
its tail from the source of thermal stimulation, e.g. flicked its tail from the light source, light 
reached the photocell and stopped the built-in timer. The time from the beginning of the 
exposure to the actual response was recorded as tail flick latency. The cut-off time of 7 s was 
used to avoid tissue damage (I and II). 
 
PAW FLICK TEST (Hargreaves et al., 1988; Le Bars et al., 2001; Yeomans and Proudfit, 1994) 
was used in the study II (model DS20, Ugo Basile, Comerio, Italy). In the test the animal was 
placed in the transparent plexiglass box which was placed on the top of the glass shield. Animal 
was allowed to freely move and settle down. Once stationary, the infrared light beam was 
projected on the plantar surface of the hind paw. The intensity of the light beam was set to 50 
arbitrary units, which in average produced a response in 2–3 s in the pilot experiments. When the 
animal reacted by withdrawing and briskly shaking or licking the hind paw ipsilateral to 
stimulation the timer was automatically stopped and the time from the beginning of the 
stimulation to the first nociceptive response was recorded. Cut-off time of 10 s was used to 
prevent the tissue damage. 
 
MECHANICAL NOCICEPTIVE THRESHOLDS were assessed in mice (II) and rats (II 
and III) with digital force gauge (Imada, DPS-1, Northbrook, IL, USA). The test is similar to 
traditional von Frey test (Le Bars et al., 2001). In the test the animals were placed on the metal 
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mesh covered with an individual Plexiglas dome. They were allowed to settle down for 1 min and 
when the animal was standing on both hind paws and the weight was equally distributed between 
the paws, the plantar surface of the hind paw was approached perpendicularly with a metallic 
monofilament. The paw was gently touched, and the force applied was steadily increased until the 
nociceptive behaviour, either a withdrawal, brisk shaking or licking of the paw, occurred. The 
paw was approached slowly and contact was made for 1 s to standardize the time-course of 
stimulation. The force initiating the nociceptive response was recorded by digital force gauge 
attached to the monofilament as a measure of a threshold of mechanical nociception. The force 
just sufficient to produce a response was applied to find out the lowest force leading to response 
– the nociceptive threshold. The monofilament with diameter of 0.2 mm was used in mice 
experiments (II) whereas 0.5 mm diameter was used in neuropathic rats (III) and 0.3 mm in 
normal, non-neuropathic rats (II). 
 
COLD ALLODYNIA was assessed with acetone test (III) (Choi et al., 1994). In the test a drop 
of acetone was applied to the plantar surface of the paw five times on both hind paws. The brisk 
withdrawal, shaking or licking of the foot was considered a nociceptive response and number of 
positive responses was recorded. In the results the ratio between positive responses and trials was 
used. 
 
4.1.3 Carrageenan inflammation 
 
Inflammatory pain was assessed in mice after the administration of different COMT inhibitors, 
OR-486, nitecapone or CGP 28014 (II). After administration of drugs the animals were briefly 
anaesthetized and received an intraplantar injection of carrageenan (Winter and Flataker, 1965a; 
1965b; Winter et al., 1962) to the plantar area of the hind paw. Nociceptive responses were 
assessed 3 h after induction of inflammation in animals receiving OR-486 or nitecapone and 3, 4 
and 5 h after induction in animals receiving CGP 28014. 
 
4.1.4 Neuropathic pain 
 
The SNL model of neuropathic pain introduced by Kim and Chung (1992), was used (III). The 
animals were anaesthetized with isoflurane (Baxter Oy, Helsinki, Finland) diluted in air (4.5% for 
induction and 2–3% for maintenance) and the left L5 and L6 spinal nerves were exposed by 
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removing a small piece of the paravertebral muscle and part of the left spinous process of the L5 
lumbar vertebra. The L5 and L6 spinal nerves were carefully isolated from the L4 spinal nerve 
and other surrounding tissues, and tightly ligated with 6–0 silk (Perma-Hand Seide, Ethicon, 
Belgium). After ligation, the muscle and the adjacent fascia were closed with sutures (Vicryl-
Rapid 3/0, Ethicon, Belgium) and the skin with metal clips. To detect any complications of 
surgery the rats were closely observed daily, and animals showing motor complications produced 
by unintended damage of L4 spinal nerve, loss of weight or any other abnormal signs were 
immediately sacrificed. 
 
4.1.5 Biochemical assays 
 
COMT ASSAY. COMT activity was measured after administration of COMT inhibitors in 
different tissues in mice (II; liver, striatum, prefrontal cortical tissue and spinal cord) and rats 
(III; intact rats: striatum and liver, SNL rats: striatum, prefrontal cortex, spinal cord L1–2, L3–4 
and L5–6 areas and sensory ganglia from the lumbar area). In mice, tissues were dissected 1 and 3 
h and in rats 0.5 – 24 h after drug administration. Tissues were rapidly dissected, cooled in plastic 
tubes on dry ice and stored in -80°C until the COMT assay. COMT assay was performed as 
described earlier (Nissinen and Männistö, 1984; Reenilä et al., 1995). Samples containing COMT 
were incubated with MgCl2 (5 mM), S-adenosyl-L-methionine (200 mM) and 3,4-dihydroxy 
benzoic acid (500 mM) in phosphate buffer (100 mM, pH 7.4) at 37°C.   
 
Enzymatic reaction gave rise to reaction products - vanillic and isovanillic acid, which were 
analysed using high-performance liquid chromatographic (HPLC) system with electrochemical 
detection. Sample dilutions were injected into the mobile phase (Na2HPO4 - EDTA – methanol) 
flowing through the column (RP-18) in which compounds being studied were separated. 
Compounds were detected with coulometric detector (Waters Spherisorb, Milford, MA, USA) 
and retention time was used to identify and peak height to quantify the reaction products. COMT 
activity was expressed as picomoles (pm) of vanillic acid formed in one min of enzymatic reaction 
per mg of protein in the sample. To assess the protein concentration of the samples, Pierce 
protein assay kit, which is based on bicinchoninic acid method, was used (Pierce, Rockford, IL, 
USA) (II and III). 
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4.1.6 Drugs 
 
OPIOIDS. Morphine hydrochloride (I) (10 mg/kg; University Pharmacy, Helsinki, Finland) was 
dissolved in physiological saline (0.9% NaCl, Natrosteril 9 mg/ml, Baxter, Vantaa, Finland) (I). 
Morphine and saline were administered subcutaneously (s.c.) in a volume of 0.1 ml/10 g of body 
weight (I). Morphine tolerance (I) was produced with a morphine pellet (National Institute of 
Drug Abuse, Bethesda, MD, USA). Pellets were implanted s.c. for 5 days and each pellet 
contained 75 mg of morphine base. Implantation was performed during the anaesthesia. 
Morphine withdrawal (I) was produced with 1 mg/kg of naloxone (The DuPont Merck 
Pharmaceutical, Wilmington, DE, USA), which was administered s.c. in a volume of 0.025 ml/10 
g. 
 
ANAESTHESIA. For the implantation of morphine pellet (I) the animals were anaesthetized 
with a s.c. injection of a mixture of midazolam (5 mg/ml, Dormicum®, Roche, Bâle, Switzerland) 
and fentanyl–fluanisone (fentanyl 0.2 mg/ml, fluanisone 10 mg/ml, Hypnorm®, Janssen 
Pharmaceutica, Beerse, Belgium) solution. Each animal received 0.4 mg of fentanyl citrate, 1.25 
mg of fluanisone, and 0.63 mg of midazolam per 10 g of body weight. Intrathecal catheters (II) 
were set under pentobarbital anaesthesia (50 mg/kg, intraperitoneally - i.p.; Mebunat Vet 60 
mg/ml, Orion Pharma, Espoo, Finland).  
 
INTRATHECAL MICROINJECTIONS. An intrathecal catheter made of a polyethylene 
(PE-10) tubing was inserted into the lumbar subarachnoid space as described by Størkson et al. 
(1996), and fixed through a layer of superficial muscles. To confirm the intraspinal location of the 
catheter lidocaine hydrochloride (Orion Pharma, Espoo, Finland) was administered through the 
catheter. An immediate paralysis of hind limbs lasting 15–30 min was considered an indicator of 
correct location of the catheter. Only rats with properly located catheters and lacking neurological 
deficits or other complications from the catheter insertion were included in the study. After 
surgery, the rats were allowed to recover before intrathecal administration of nitecapone for 4 
days. 
 
COMT inhibitors. Nitecapone (II and III) [OR-462, 3-(3,4-dihydroxy-5-nitrobenzylidene)- 2,4-
pentanedione], OR-486 (II) and CGP 28014 [N- (2-pyridone-6-yl)-N’,N’-di-n-
propylformamidine] (II) were synthesized by Dr. Aino Pippuri (Orion Pharma, Espoo, Finland) 
using methods described earlier (Bäckström et al., 1989). For the systemic administration studies 
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(II and III), the COMT-inhibitors were suspended in 0.5% (w/v) carboxymethylcellulose (CMC) 
(Fluka AG, Buchs SG, Switzerland) and administered i.p. in volume of 7.5 ml/kg for mice and 
3.3 ml/kg for rats. The dose of COMT inhibitors was 30 mg/kg. For the intrathecal 
administration (II), nitecapone was dissolved in 30% (w/v) hydroxypropyl-ß-cyclodextrin (Acros 
Organics, Geel, Belgium) dissolved in sterile physiological phosphate-buffered saline (pH 7.4) 
and administered in a volume of 10 μl into the lumbar subarachnoid space. 
 
CARRAGEENAN. Carrageenan (II) (Sigma, St. Louis, MO, USA) was dissolved in 
physiological saline (0.9% NaCl, Natrosteril 9 mg/ml, Baxter, Vantaa, Finland) to give a 2% 
(w/v) solution and administered in a volume of 40 μl into the plantar region of the right hind 
paw. 
 
Fig. 5. COMT activity – rats. COMT activity in the liver and striatum of male Wistar rats after acute 
administration of nitecapone (30 mg/kg, i.p.). Tissue samples were collected 0.5 (n=7), 1 (n=6) and 3 h 
(n=3) after nitecapone administration. COMT activity of the untreated control group (n=8) is plotted at 0 
min. Activity is normalised to that of the control group (mean activity = 100%). Asterisks indicate a 
difference as compared with the control group (1-way ANOVA: p<0.0001; Bonferroni-correction: **, 
p<0.001; ***, p<0.0001). 
 
 
COMT inhibitor considerations. The purity of the compounds was checked by thin layer 
chromatography and nuclear magnetic resonance, and it was always better than 99%. The 
efficacy/biological activity of the COMT inhibitors used in behavioural studies (II and III) was 
verified by ex vivo measurements of COMT activity in rats (Fig. 5) and mice (Fig. 6). 
46 
 
 
Fig. 6. COMT activity – mice. (A) Striatal catechol-O-methyltransferase (COMT) activity in male 
C57/BL6J mice 1 and 3 h after i.p. administration of 3,5-dinitrocatechol (OR-486) (30 mg/kg; 1 h, n=7; 3 
h, n=13) or nitecapone (30 mg/kg; 1 h, n=8; 3 h, n=16). Baseline (0 h) represents COMT activity of vehicle 
treated animals (n=21). **p<0.01; ***p<0.001 vs. vehicle group; 1-way ANOVA followed by a Bonferroni 
test. (B) Hepatic COMT activity after the same i.p. treatment as above (OR-486: 1 h, n=7; 3 h, n=6; 
nitecapone: 1 h, n=8; 3 h, n=5; vehicle: n=12). **p<0.01 vs. vehicle group. 
 
 
 
4.2 Humans 
 
4.2.1 General 
 
SUBJECTS. Study IV reports the data of 1000 female patients treated for breast cancer. For this 
sample 1149 patients of the 1536 eligible consecutive patients with unilateral non-metastasized 
breast cancer who enrolled for surgical treatment at the Unit for Breast Surgery at the Women's 
Hospital, Helsinki University Central Hospital, between August 2006 and December 2010, were 
asked to participate in the study. The specific types of surgery were modified radical mastectomy 
or breast conserving mastectomy (resection), with or without sentinel biopsy and/or axillary 
clearance (AC). The study cohort is described in detail in Kaunisto et al. (2013). 
 
INITIAL CLINICAL ASSESSMENT. Following informed consent acquisition, medical and 
medication demographic history was taken. The patients filled in questionnaires about depression 
(Beck Depression Inventory; Beck et al., 1961) and anxiety (State and Trait Anxiety Inventory, 
STAI) (Spielberger et al., 1983). Both have been validated for this particular group of patients and 
they have been used in previous studies (Tasmuth et al., 1996). 
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ANAESTHESIA. The patients were premedicated with diazepam 2.5-15 mg and paracetamol 1 
g orally. The patients were anaesthetized with i.v. infusions of remifentanil (0.05-0.25 
μg/kg/min), and propofol (2-3 mg/kg for induction and 50-100 μg/kg/min for maintenance). 
Rocuronium was used to achieve sufficient muscle relaxation and to facilitate tracheal intubation. 
During the closure of skin, fentanyl (1 μg/kg, i.v.) was given and the infusion of remifentanil was 
stopped. At the same time neostigmine (2.5 mg) with glycopyrrolate (0.5 mg) were administered 
i.v. to reverse the neuromuscular block. Blood specimen was drawn for DNA isolation and 
banking during anaesthesia to avoid unnecessary injections. 
 
 
4.2.2 Pain measurements in humans 
 
EXPERIMENTAL PAIN. All tests were carefully explained to the patients before the 
experiment. Contact heat pain was assessed using the 16 mm x 16 mm thermode of the TSA-II 
NeuroSensory Analyzer (Medoc Ltd., Ramat Yishai, Israel). A temperature of 43°C and 48°C was 
exposed, in this order, once each, for 5 s on the antebrachium contralateral to surgery. Patients 
assessed the intensity and unpleasantness of pain with a 0 to 10 Numerical Rating Scale (NRS) at 
the end of the test. Zero represented ‘‘no pain”, and 10 ‘‘maximal pain imaginable”. 
 
Cold pain was measured by immersing the hand to cold (3°C) water bath (JULABO, U.S.A.) for 
the maximum of 90 s or for less depending on for how long the patient could tolerate the test. 
Time to withdrawal, and pain intensity (NRS) and unpleasantness were measured at withdrawal 
and every 15 s during the test. Cold pain test was not performed to the first 100 patients studied 
(n=900). Those patients who withdrew their hand before the analyzed time point were coded as 
having the maximum NRS value (n=118 at 15 s, n=353 at 30 s). 
 
POSTOPERATIVE PAIN ASSESSMENT and administration of oxycodone. In the post 
anaesthesia care unit (PACU) the patients were asked to rate their pain intensity at rest and during 
motion using NRS. Motion pain was assessed by asking the patient to raise the arm ipsilateral to 
surgery up to 90°. Patients were titrated with i.v. oxycodone by the research nurse who asked 
about the pain intensity every 5 min and administered oxycodone in doses of 1-3 mg until 
adequate analgesia (NRS<4/10) was achieved. After this pain intensity was asked every 15 min 
until the patient needed the next dose of oxycodone. The required quantity of oxycodone was 
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recorded. For the ward the patients were provided with a patient-controlled analgesia device 
(PCA) for up to 20 hrs. The total amount of oxycodone consumed after the operation, including 
both, the titration at the PACU and PCA consumption was recorded. Any incidents of adverse 
events were recorded.  
 
SNP SELECTION and GENOTYPING. A total of 22 SNPs were selected for genotyping 
from a 40 kb region covering the COMT gene as well as the 5´UTR and 3´UTR regions. The 
SNP selection was based on both the phase 2 and phase 3 data of the HapMap database 
(http://www.hapmap.org).  The SNPs that captured most of the genetic information (tagging 
SNPs) were selected using the Tagger program included in the Haploview 4.1 software (Daly 
Lab, MIT/Harvard Broad Institute). The SNPs were chosen to capture all known HapMap SNPs 
having a minor allele frequency >10% in the Caucasian population with pair-wise r2 0.9. Some 
additional SNPs were selected from the dbSNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP) based on their position on the exonic areas. 
 
DNA was extracted from peripheral blood using the Autopure LS automated DNA purification 
instrument (Gentra Systems, Inc., Minneapolis, MN, USA). The 22 SNPs were genotyped using 
the Sequenom MassARRAY system and the iPLEX Gold Single Base Extension chemistry 
(Sequenom, San Diego, CA, USA) (Jurinke et al., 2002) in a multiplex format. This method has 
excellent success (>95%) and accuracy (100%) rates (Lahermo et al., 2006).  
 
 
4.3 Ethics 
 
Animal experiments were performed according to the guidelines of local authorities, The 
International Association for the Study of Pain (Zimmermann, 1983) and Guide for the Care and 
Use of Laboratory Animals by the National Institutes of Health 
(http://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-Use-of-Laboratory-Animals.pdf). 
All experiments were approved by the provincial government of Southern Finland (I-III). 
 
In the clinical study (IV), the patients were fully informed of the procedures and potential risks 
and the study was explained to them in detail before the enrolment. Participants were fully 
apprised of their right to withdraw from the study at any time. Written informed consent was 
obtained from each subject participating in the study by a research nurse or a physician. Surgery 
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and all other treatments were part of the patients’ normal clinical care and were carried out under 
the supervision of the physician in charge. The research protocol had been approved by the 
coordinating ethics committee (136/E0/2006) and the ethics committee of the Department of 
Surgery (Dnro 148/E6/05) of the Hospital District of Helsinki and Uusimaa (HUS). All 
reasonable precautions have been taken to prevent loss of confidentiality. All specimens and 
clinical data files have been coded, and subject names or identifying information are not to be 
released. 
 
 
4.4 Data analysis 
 
In data analysis of experimental animal studies (I-III), parametrical tests (Student’s t test, analysis 
of variances, ANOVA) with suitable post hoc tests were used when the criteria for parametrical 
analysis were met. In assays where cut off-time was used, data was not normally distributed, not 
continuous or variances were not equal, corresponding non-parametrical analysis were used. In 
the text and figures, the results are presented as means ± standard error of the mean (SEM) of n 
observations. P < 0.05 was considered as a limit of statistical significance in all tests. Area under 
the time-effect curve (AUC) has been calculated using trapezoidal rule.  
In the human study (IV), genotype distributions in the whole sample were tested for the Hardy-
Weinberg equilibrium applying the Ȥ2 method. The Haploview 4.0 program was used to 
determine the pair-wise LD between the SNPs (r2-value) and to identify haploblock structures 
using the confidence interval algorithm. In association analyses all phenotypes were adjusted for 
potential confounding factors i.e. residual phenotypic scores after regressing out covariate effects 
were used. All phenotypes were adjusted for age, body mass index (BMI), presence of 
preoperative chronic pain condition, and anxiety (STAI) score. Postoperative variables were also 
adjusted for the type of surgery performed. These factors have been shown to modulate the pain 
phenotypes of our study (Kaunisto et al., 2013). In addition to the phenotypes used in Study IV 
also cold pain intensity at 45 s, intensity of postoperative motion pain upon awakening, time of 
administration of first oxycodone and intensity of postoperative pain at rest before the 
administration, amount of oxycodone administered in PACU and amount of oxycodone required 
to achieve satisfactory analgesia were analysed for associations with COMT SNPs and haplotypes, 
and cold pain intensity at 60-90 s and heat pain intensity at 43°C for associations with COMT 
SNPs. Association between the COMT genotypes and pain phenotypes was tested using linear 
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regression analysis. Additive, dominant and recessive models were all considered. Additive model 
presumes the genotype effect on studied phenotype is r for heterozygous variant carriers, 2r for 
homozygous carriers, and 0 for non-carriers (Lewis, 2002). Dominant model presumes that the 
genotype effect is dominant and its effect on phenotype is r in both, homozygous and 
heterozygous variant carriers. Recessive model presumes recessive genotype effect, which 
requires both variant alleles and thus homozygous carriers are compared to the rest of the 
population. Analyses were performed with PLINK software (Purcell et al., 2007). In the 
haplotype analysis homozygous haplotype carriers were compared with heterozygous carriers and 
non-carriers. In Study IV, the additive model was used. The data was complemented by 
additional analyses using dominant and recessive models, which are also shown in this summary 
(Kambur and Kalso, 2012, unpublished data). As some of the studied quantitative traits were not 
normally distributed, permutation procedures were used to obtain empirical p-values and p-values 
adjusted for performing multiple tests in order to control for the family-wise error rate. This 
method takes into account the correlation due to LD between the studied SNPs and thus 
provides a less stringent correction than using a Bonferroni correction to control for multiple 
testing. The level of statistical significance was set at an experiment-wise corrected p=0.05. The 
associations were calculated with PLINK software using the max(T) permutation option in which 
produces 10000 permutations are being performed for each SNP. Results were not adjusted for 
the number of examined phenotypes. In the results, in addition to naive empirical p-values 
shown in the tables and corrected p-values described in the text, also ȕ-values have been 
reported. ȕ is the variable which reflects the magnitude and direction of the effect of genotype in 
each analysis. If ȕ is negative, phenotype values of study group, which is minor allele or 
haplotype carriers, are smaller as compared with control group. Magnitude of ȕ reflects size of 
the effect – difference between the groups and is proportional to the unit size of compared 
phenotype. Thus, ȕ should be interpreted in the context of the analysed phenotype. In some 
cases associations were verified by ANOVA or other parametrical tests. In addition, interactions 
between rs165774 and rs887200 and LPS/APS/HPS-haplotypes were assessed by epistatic 
interaction analysis which is based on linear regression, using PLINK software. 
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5 RESULTS 
 
 
5.1 Comt knockout mice and stress- and opioid-induced 
analgesia (I) 
 
In mice, a knockout of Comt gene decreased endogenous (Fig. 7) and opioid-induced (Fig. 8) 
analgesia as measured by latency to spinal withdrawal reflex in the tail flick test. It also increased 
opioid-induced analgesia as measured by latency to more complex nociceptive behaviour, e.g. 
licking or brisk shaking of the hind paw, in the hot plate test (Fig. 8). 
 
 
 
 
Fig. 7. Stress-induced analgesia in wild-type (WT; n=20) and Comt knockout (KO; n=17) mice. 
Stress-induced analgesia was measured with tail flick (A) and hot plate (B) tests. Asterisk (*) indicates a 
statistically significant difference as compared with the respective baseline (p<0.0001), whereas hash (#) 
indicates a statistically significant difference between the knockout and wild-type mice at respective time 
points (p<0.05). 
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Fig. 8. Antinociceptive effect of morphine in Comt knockout (KO) and wild-type (WT) mice. 
Nociception was assessed with the tail flick (A) and hot plate (B) tests before and after administration of 
morphine (10 mg/kg s.c., n=10-13) and vehicle (n=4-6). Results are presented as percentages of the 
maximum possible effect (MPE%) The symbols indicating the knockout group are moved slightly to the 
right to allow all symbols to be visible. Asterisk (*) indicates a statistically significant difference as compared 
with the wild-type (p<0.05). 
 
 
 
 
5.2 COMT inhibitors and acute and inflammatory pain (II) 
 
OR-486, increased thermal and mechanical nociception after acute (Fig. 2) and repeated (Fig. 9) 
peripheral (i.p.) administration in models of acute nociception in mice. 
 
 
 
Fig. 9. A. Mechanic nociceptive thresholds after repeated administration of OR-486 (30 mg/kg, 
i.p., n=16), nitecapone (30 mg/kg, i.p., n=16), or vehicle (n=21). Results are expressed in grams. 
Statistics: *** p<0.001 vs. vehicle group (Bonferroni-correction). B. Baseline nociceptive latencies in the 
hot plate test after repeated administration of OR-486 (30 mg/kg, i.p., n=16), nitecapone (30 
mg/kg, i.p., n=16), or vehicle (n=21). Results are expressed as percentages of the maximum possible 
effect (MPE%). Statistics: **p<0.01; ***p<0.001 vs. vehicle group (Bonferroni-correction). 
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The same effects were seen after acute (Fig. 2) and repeated (Fig. 9) (i.p.) administration of 
nitecapone. Both inhibitors increased the pronociceptive effects of carrageenan inflammation by 
an order of magnitude that was similar to that in the non-inflamed paws used as controls (Fig. 
10). Similar effects were also seen after i.p. administration of CGP 28014. Nitecapone, however, 
was pronociceptive only after peripheral administration and did not increase nociception when 
administered i.t. to rats. 
 
 
 
 
Fig. 10. Effect of repeated administration of OR-486 (30 mg/kg, i.p., n=16), nitecapone (30 mg/kg, 
i.p., n=16) and vehicle (n=21) on paw flick (A) responses in inflamed and non-inflamed paws, and 
hot plate (B) responses 3 h after induction of carrageenan inflammation. Statistics: *p<0.05; 
**p<0.01; ***p<0.001 vs. corresponding paw of the vehicle group (A) or vehicle group (B) (Bonferroni-
correction).  
 
 
 
 
5.3 COMT inhibitors and neuropathic pain (III) 
 
In a model of neuropathic pain, repeated nitecapone treatment (30 mg/kg, i.p., once a day), 
reduced nociceptive symptoms in rats after SNL for a long period of time far exceeding the 
duration of COMT inhibition (Fig. 11 and 12). It reduced both cold allodynia and mechanical 
hyperalgesia. Nitecapone treatment was effective when started before the operation (Fig. 11) but 
also when initiated only 2 days after the operation (Fig. 12), when neuropathic symptoms were 
already developed. 
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Fig. 11. Effect of nitecapone (30 mg/kg, i.p., n=11) or vehicle (n=11) pretreatment on (A) 
thresholds for mechanical stimuli and (B) responses to cold stimuli after spinal nerve ligation. 
Times of administration are indicated by the minor ticks on the x-axis. Results are expressed in grams (A) 
and as a number of positive responses out of 5 trials (B). Cold allodynia responses of treatment groups over 
time were compared using the areas under the time-effect curves (C, AUC, days 2-14) Asterisks indicate a 
statistically significant difference between the treatment groups, A: 2-way RM ANOVA: effect of treatment, 
p<0.001; Bonferroni-correction: *, p<0.05; **, p<0.01; ***, p<0.001; C: Mann-Whitney U-test: *, p<0.05. 
 
 
Fig. 12. Effect of nitecapone treatment on (A) thresholds for mechanical stimuli and (B) responses 
to cold stimuli after spinal nerve ligation. Nitecapone (30 mg/kg, i.p., n=9) or vehicle (n=10) treatment 
was started on the second day after surgery and continued once daily for 20 days. Results are expressed in 
grams (A) and as a number of positive responses out of 5 trials (B). Times of administration are indicated 
by the minor ticks on the x-axis. Treatment groups over time were compared using the areas under the 
time-effect curves (C, AUC, days 4-20). Asterisks indicate a difference between the treatment groups (A: 2-
way RM ANOVA: effect of treatment, p<0.001; Bonferroni-correction: *, p<0.05; **, p<0.01; ***, 
p<0.001; C: Mann-Whitney U-test: *, p<0.01).  
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5.4 Genetic variation in COMT and pain sensitivity in humans 
(IV) 
 
5.4.1 Patients: demographic description and experimental and clinical pain 
 
The demographic data, types of breast cancer surgery, results of the experimental pain tests and 
postoperative pain and need of oxycodone are shown in Table 2. 
 
 
Table 2. Demographic and nociceptive description of patients. 
 
PHENOTYPE 
 
AVERAGE 
 
STANDARD 
DEVIATION 
n 
 
Age (yr) 57.0 9.3 1000 
BMI 25.4 4.3 1000 
Breast conserving surgery with SNB   420 
Breast conserving surgery with AC   206 
Mastectomy with SNB   140 
Mastectomy with AC   234 
Heat pain intensity (43°C) 0.7 1.4 992 
Heat pain intensity (48°C) 3.5 2.4 990 
Cold pain intensity (15s) 5.0 2.5 782 
Cold pain intensity (30s) 6.2 2.4 546 
Cold pain intensity (45s) 6.9 2.4 387 
Cold pain intensity (60s) 7.1 2.2 297 
Cold pain intensity (75s) 7.1 2.2 240 
Cold pain intensity (90s) 7.3 2.2 216 
Cold pain tolerance (total time, s) 46.4 29.5 900 
Rest pain before 1st oxycodone dose 5.0 1.5 959 
Motion pain before 1st oxycodone dose 5.0 1.5 952 
 
Intensity of pain was assessed with a numerical rating scale (NRS 0-10). Abbreviations: SNB - sentinel node biopsy, 
AC - axillary clearance. 
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5.4.2 Genotyped SNPs and haploblocks 
 
In addition to analysed SNPs (Table 3), haplotype analysis was performed (Kambur and Kalso, 
2012, unpublished data). Three haploblocks were formed (Fig. 13). Five haplotypes having a 
frequency above 1% could be constructed within block 1, and six haplotypes within blocks 2 and 
3. 
 
Table 3. Genotyped COMT  SNPs. 
SNP POSITION 
ALLELES 
MINOR/MAJOR
OBSERVED 
HETEROZYGOSITY
P-VALUE 
(Hardy-Weinberg 
Equilibrium) 
MINOR ALLELE 
FREQUENCY 
rs6518591 chr22:18304021 G/A 0.262 0.4486 0.162 
rs737866 chr22:18310109 G/A 0.327 0.9025 0.208 
rs737865 chr22:18310121 C/T 0.328 0.9107 0.209 
rs1544325 chr22:18311668 A/G 0.524 0.2598 0.492 
rs8185002 chr22:18313048 G/T 0.33 0.9948 0.206 
rs174675 chr22:18314051 T/C 0.417 0.802 0.302 
rs5993882 chr22:18317533 G/T 0.299 0.4586 0.191 
rs740603 chr22:18325177 G/A 0.488 0.731 0.398 
rs4646312 chr22:18328337 C/T 0.424 0.7884 0.313 
rs4633 chr22:18330235 C/T 0.504 0.7718 0.457 
rs2239393 chr22:18330428 G/A 0.43 0.9021 0.317 
rs4818 chr22:18331207 G/C 0.425 0.8359 0.313 
rs4680 chr22:18331271 G/A 0.505 0.7154 0.457 
rs4646316 chr22:18332132 T/C 0.313 0.2613 0.207 
rs165774 chr22:18332561 A/G 0.378 0.6578 0.244 
rs174696 chr22:18333176 C/T 0.439 0.4008 0.351 
rs9306235 chr22:18335157 A/G 0.114 1 0.06 
rs9332377 chr22:18335692 T/C 0.217 0.9743 0.122 
rs165599 chr22:18336781 G/A 0.457 0.408 0.327 
rs887199 chr22:18341955 A/G 0.319 0.9301 0.201 
rs2518824 chr22:18342963 G/T 0.076 0.7802 0.038 
rs887200 chr22:18343666 C/T 0.27 0.7455 0.164 
 
SNPs with effects on COMT activity or expression are shown with bolding (Bray et al., 2003; Lotta et al., 1995; 
Meloto et al., 2012; Nackley et al., 2006; Tsao et al., 2011). 
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5.4.3 COMT  polymorphisms and pain: SNPs  
 
In the patients several of the studied COMT SNPs (Table 3; Fig. 13) showed association 
(p<0.05) with experimental pain (Appendix 1: Tables 4-5).  
 
SNPs rs165774, rs174696 and rs8185002 were associated with intensity of pain after 48°C 
stimulation and rs737866 and rs737865 showed borderline associations (0.05<p<0.1) (Appendix 
1: Table 4). Minor alleles of  rs165774 (A), rs8185002 (G), rs737866 (G) and rs737865 (C) 
decreased pain intensity (Ƣ=-0.300-0.464), whereas rs174696C increased pain intensity (Ƣ=0.48). 
Rs165774 showed the strongest association and remained significant also after correction for 
multiple comparisons (p=0.04). Minor alleles of rs4646312 (C), rs2239393 (G) and rs4818 (G) 
showed a trend towards increased pain intensity after 43°C stimulation which lacked statistical 
significance (p=0.08-0.088). 
 
Fig. 13. Graphical representation of COMT SNPs, haplotypes, and linkage disequilibrium structure studied 
in patients (n=1000) undergoing breast cancer surgery. Numbers inside the square represent the linkage 
disequilibrium value between two SNPs and is 100 x D´. |D´| varies between 0 (no disequilibrium) and 1 (maximum 
disequilibrium), and its value is colour-coded by shades of white to grey to black. Initiation (MB-COMT and S-
COMT) and the stop (TGA) codons as well as rough location of promoter regions (P1 and P2) are also shown. 
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In cold pain intensity the strongest association was seen with rs887200, which was also associated 
with cold pain tolerance. Its phenotype effect was strongest and sustained the multiple 
comparison corrections (Fig. 14; Appendix 1: Table 5). The minor allele (C) was associated with 
decreased pain intensity and increased tolerance (recessive model). Also the minor allele of 
rs1544325 (A) was associated with increased pain intensity (dominant model) (45s, p=0.005, 
Appendix 1: Table 5; 60s, p=0.004, data not shown)(Kambur and Kalso, 2012, unpublished data). 
Rs1544325A also showed the most significant associations with cold withdrawal time, together 
with the minor allele of rs2239393 (G) (p=0.007, dominant and recessive models, respectively).  
 
Several other SNPs of the first (rs737866 and rs737865) and the second (rs4646312C, rs4818G, 
rs4646316T and rs165774A) haploblocks as well as rs9306235, which is located between the 2nd 
and 3rd haploblocks showed associations with cold pain phenotypes. In general, minor alleles of 
the first haploblock SNPs (G and C, respectively) decreased pain intensity and increased time to 
withdrawal, whereas minor alleles of the other SNPs (rs4646312C, rs4818G, rs4646316T, and 
rs9306235A) had an opposite effect (Appendix 1: Table 5). SNP rs165774A, which was 
associated with decreased heat pain intensity, was associated with decreased cold pain intensity 
(90s, p=0.03, Ƣ=-0.23; data not shown). However, only association of rs887200 sustained multiple 
comparison corrections.  
 
Clinical postoperative pain was associated with SNPs rs4646312, rs2239393 and rs4818, which all 
are located within the same (middle) haploblock (p=0.006-0.007)(Kambur and Kalso, 2012, 
unpublished data; Appendix 1: Table 6). SNP rs4680 was not significant. In all three SNPs the 
minor allele (C, G and G, respectively) carriers had higher postoperative pain scores than the 
patients being homozygous for the major allele (Ƣ=0.25-0.30). After corrections for multiple 
comparisons, association signals did not reach statistical significance (p=0.08-0.1)(data not shown). 
In phenotypes related to oxycodone consumption, there was an association with SNPs rs174696 
and trends with rs740603, rs9332377 and rs887200 (p=0.07-0.1), which did not sustain multiple 
comparison corrections. 
 
5.4.4 SNP rs887200 
 
SNP rs887200 was for the first time shown to alter intensity to experimental pain. It was detected 
in the initial linear regression analysis, showing association with the intensity of cold pain at 30s. 
It was analysed further and it was associated with the intensity of cold pain consistently at all time 
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points (Fig. 14A) as well as tolerance to cold pain (Fig. 14B). A similar trend was also seen in the 
intensity of pain after noxious heat stimulation but failed to reach statistical significance (unpaired 
Student’s t test, p=0.1; Fig. 14C). Also in the oxycodone phenotypes, there was a trend as minor 
allele carriers needed more oxycodone to achieve satisfactory analgesia and they also received 
more oxycodone in the PACU (Kambur and Kalso, 2012, unpublished data). Signals of oxycodone 
phenotypes, however, did not sustain multiple comparison corrections. 
 
 
5.4.5 COMT polymorphisms and pain: haplotypes 
 
For experimental pain phenotypes heat pain intensity showed the strongest association signal 
with haplotype TTACACA of block 2 (dominant model, uncorrected p=0.003, Ƣ=-0.463), which 
has a frequency of 24% (Appendix 1: Table 7). It also showed a trend toward decreased mean 
intensity of cold pain, but effect was not significant (p=0.097, Ƣ=-0.212). This haplotype was the 
only haplotype containing the minor allele (A) of the SNP rs165774, which was associated with 
heat pain in single SNP analyses. Within the block 1 haplotype AGCGGCT decreased intensity 
of heat pain (dominant model, uncorrected p=0.04, Ƣ=-0.320). It showed a trend toward 
decreased cold pain intensity at 30s and 45s (dominant model, uncorrected p=0.061-0.08, Ƣ=-
0.284 -0.317) and prolonged withdrawal time (dominant model, uncorrected p=0.054, Ƣ=3.898). 
 
In the cold pain phenotypes haplotype AATATCT of block 1 showed the strongest associations 
and increased pain intensity at all time points (dominant model, uncorrected p=0.008-0.034, 
Ƣ=0.483-0.512) and correspondingly shortened time to withdrawal (dominant model, uncorrected 
p=0.005, Ƣ=-6.252). After statistical corrections, however, these associations did not reach the 
level of statistical significance (p=0.068-0.1). Another haplotype of the same block, AATGTTT 
decreased pain intensity (dominant model, mean intensity, uncorrected p=0.032, Ƣ=-1.425; 45s 
p=0.008, Ƣ=-2.028). Among block 2 haplotypes CCGGGTG increased cold pain intensity at 30 s 
(p=0.024, Ƣ=0.359) and 45 s (p=0.042, Ƣ=0.272) as well as mean pain intensity (p=0.031, 
Ƣ=0.25), and decreased the withdrawal time (p=0.044, Ƣ=-10.84). Haplotype TCACGCG instead, 
decreased cold pain intensity (30 s, p=0.003, Ƣ=-1.8; 45 s, p=0.02, Ƣ=-1.203; mean, p=0.011, Ƣ=-
1.14), and increased cold withdrawal time (p=0.029, Ƣ=14.99). It also showed a trend towards 
decreased intensity of heat pain (recessive p=0.089, Ƣ=-0.913). Association with cold pain 
intensity at 30s sustained after corrections for multiple comparisons (p=0.033).  
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Fig. 14. A. Effect of SNP rs887200 on cold pain intensity. Asterisks indicate a statistically significant 
difference between the genotypes (2-way ANOVA for repeated measurements, effect of genotype, p<0.0001). 
B. Effect of SNP rs887200 on cold pain tolerance. Asterisks indicate a statistically significant difference 
between the genotypes (unpaired Student’s t test, **p<0.01). C. Effect of SNP rs887200 on intensity of pain 
after 5 s stimulation with noxious heat (48°C). P-value indicates the difference between the genotypes (unpaired 
Student’s t test). D. Effect of SNP rs887200 on the amount of oxycodone (mg) administered in post 
anaesthesia care unit (PACU). P-value indicates a statistically significant difference between the genotypes 
(unpaired Student’s t test).  
 
 
As rs887200 which showed the best single SNP association to cold pain, the haplotypes 
containing its minor allele were of special interest. Two haplotypes within block 3 had this allele. 
Of these, only the more common haplotype CGATC showed a trend towards lower cold pain 
intensity and prolonged withdrawal time. There were no associations between haplotypes and the 
phenotypes of postoperative pain or oxycodone consumption. 
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Among LPS, APS and HPS haplotypes LPS (CGG) was associated with increased pain intensity 
and shorter withdrawal times. HPS-haplotype (CCG) showed opposite effects under the recessive 
model which remained after corrections for multiple comparisons (p=0.009). LPS-haplotype also 
showed association with increased intensity of postoperative pain under dominant model, which 
sustained multiple comparison corrections (p=0.02)( Appendix 1: Table 8).  
 
5.4.6 Interactions 
 
In cold pain phenotypes there was an interaction between rs887200 and HPS (CCG)-haplotype 
and they together were associated with decreased intensity of cold pain (30s, p=0.003) and 
increased time to withdrawal (Kambur and Kalso, 2012, unpublished results). Similar interaction was 
seen in heat pain intensity. Rs887200 also showed interaction with APS (TCA)-haplotype also 
decreasing cold pain intensity (30s, p=0.04). There were no interactions between rs165774 in any 
of the experimental pain phenotypes. 
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6 DISCUSSION 
 
 
6.1 Main findings 
 
 
RODENTS. Comt knockout mice showed enhanced response to morphine in the hot plate test. 
In the tail flick test, which measures mainly spinal responses, Comt knockout mice lacked stress-
induced analgesia, and their response to morphine was attenuated. Acute administration of both 
OR-486 and nitecapone increased mechanical and thermal nociception in mice, and these effects 
persisted after 5 days of repeated treatment. Both COMT inhibitors also increased the 
pronociceptive effects of carrageenan-induced inflammation. In Comt deficient mice, OR-486 
failed to influence pain-related behaviour. In contrast to these findings, nitecapone reduced 
symptoms of neuropathic pain induced by the SNL. The development of mechanical and cold 
allodynia was partially prevented by treatment that started before surgery, and similar 
antiallodynic effect was achieved when the treatment started on the 2nd day after induction of 
neuropathy. 
 
HUMANS. In breast surgery patients, the main finding was that the 3´UTR SNPs, rs887200 and 
rs165774 had the most significant effects on pain phenotypes. Effects of both SNPs on pain 
phenotypes were shown here for the first time. Both SNPs represent completely novel 
mechanisms of action, and in rs165774 the mechanism involves the formation of an alternatively 
spliced COMT variant (Meloto et al., 2012). The magnitude of their effect exceeded the effects of 
other SNPs and associations sustained after all statistical corrections.  The variants which have 
received virtually most of scientific attention so far, were insignificant. Several SNPs or 
haplotypes, however, were associated with experimental or clinical pain phenotypes (uncorrected 
p<0.05). 
 
Based on these results, a low or lacking COMT activity in rodents is associated with 
pronociception in thermal, mechanic, and inflammatory pain models, while the situation is 
reverse in the neuropathic pain models. These fairly unanimous findings, in a frame of pain 
models, allow a discussion of the mechanisms based on COMT substrates, their localization in 
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the pain tract and properties of COMT inhibitors. In humans, several SNPs were associated with 
pain phenotypes. For some SNPs there is some evidence regarding their molecular mechanism of 
action, but in most cases, their relation to COMT activity is not known. Therefore, in human 
patients it is rather relevant to discuss the relationship of COMT gene mutations than COMT 
activity, and pain.  
 
 
6.2 Why does low COMT activity enhance pain? 
 
The mechanisms underlying the effect of COMT inhibition and decreased COMT activity on 
nociception are unknown, however several hypotheses have been offered. COMT is expressed in 
several parts of nervous system that are involved in processing of nociception in the brain, as well 
as in spinal and peripheral structures.  In the periphery, COMT is expressed in ganglia of the 
primary sensory neurons and in the spinal cord in superficial laminae of the dorsal horn (Hong et 
al., 1998; Karhunen et al., 1996). In the brain, COMT is expressed in several brain regions 
receiving nociceptive input from spinothalamic pathway, such as prefrontal cortex. A 
subpopulation of projecting neurons of another ascending nociceptive tract, the spinobulbar 
pathway, targets the regions in the brainstem, which contain catecholamine cell groups (A1-A2, 
A5-7, C1; Wall et al., 2006). These areas integrate nociception with homeostatic, cardiorespiratory, 
and behavioural state processes, and modulate nociception at spinal and forebrain level. They 
also contain pre-autonomic neurons and regulate sympathetic activity in the periphery, offering 
another site of modulation where COMT could play a role. A1 neurons also project to the 
hypothalamus regulating the release of ACTH after trauma or noxious stimulation.  ACTH is part 
of HPA-axis and it is released as a response to pain or trauma. It affects pain and stress 
responses, and is associated with chronic pain conditions such as fibromyalgia. Polymorphisms in 
COMT gene modulate endocrine stress responses of HPA convergently with polymorphisms in 
other genes of monoaminergic system (Jabbi et al., 2007). 
 
Initially, it was suggested that pronociceptive effects of low COMT activity are mediated via 
changes in the endogenous opioid system (see in details below, 6.4.2) (Zubieta et al., 2003). As 
short-term administration of COMT inhibitors, while showing clear pronociceptive effects (II), 
did not modify opioid analgesia in mice, a lack of changes in opioid system is obvious (Kambur 
and Männistö, 2009, unpublished results). Therefore, pronociceptive effects of COMT inhibitors or 
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COMT polymorphisms cannot be explained by changes in synthesis of proteins in endogenous 
opioid system and also other complementary mechanisms have been suggested (Nackley et al., 
2007) (I and II). It seems that most of the studies, directly and indirectly, support the 
involvement of noradrenergic or adrenergic transmission in mediating the effects of low COMT 
activity on pain (Khasar et al., 1999; Liang et al., 2006; Nackley et al., 2007; Meloto et al., 2012; 
Tchivileva et al., 2010). 
 
ß2 and ß3 receptors. It has been shown that some of the effects of COMT are blocked by 
adrenergic ß2 or ß3 receptors antagonists (Nackley et al., 2007). The density of adrenergic ß2/3-
receptors in the DRG is low, but is generally high in peripheral tissues and several parts of the 
brain (Nicholson et al., 2005). The origin and nature of substances causing activation of ß2 or ß3 
receptors are not known. Peripheral ß2 or ß3 receptors can be activated by noradrenaline released 
from sympathetic nerve endings, or by circulating catecholamines delivered to the site of action 
via the blood stream. It has been shown that in the DRG-neurons noradrenergic activation of Ƣ3-
receptors stimulates the release of ATP, which can contribute to pain symptoms (Kanno et al., 
2010). On the other hand, a chronic stimulation of Ƣ3-receptors also increases the expression of 
mitochondrial uncoupling proteins (UCPs), which are found in primary sensory neurons that also 
express substance P (Horvath et al., 2002), a pronociceptive peptide that lowers nociceptive 
thresholds (Horvath et al., 2002a,b; Weyer et al., 1999). UCPs represent an uncoupling pathway 
acting by proton sink mechanism, which allows mitochondria to avoid excessive production of 
ROS and to maintain a high rate of O2 consumption (Guerrero-Castillo et al., 2011). 
 
COMT inhibitors can cause uncoupling of mitochondrial phosphorylation, supporting 
noradrenergic Ƣ3-mediated increase in UCP expression in sensory neurons as explanation for 
pronociceptive effects of COMT inhibitors (Borges, 2005,2003). A possible role of UCP in 
pronociceptive effects of COMT, however, has not been studied and requires further 
investigation. If pronociceptive effects are UCP-mediated, Ƣ-blockers could possibly also prevent 
other, non-nociceptive effects of mitochondrial uncoupling associated with COMT inhibitors.   
 
DOPEGAL. It has been proposed that 3,4-dihydroxyphenyl-glycolaldehyde (DOPEGAL), a 
catecholamine metabolite formed by MAO, can produce potent mechanical hyperalgesia, and it 
may explain pronociceptive effects of catecholamines synthesized in primary peripheral 
nociceptors (Dina et al., 2008). Under normal conditions, aldehyde reductase metabolizes 
DOPEGAL to 3,4-dihydroxyphenylglycol, which is further methylated by COMT to 3-methoxy-
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4-hydroxyphenyl-glycol. Thus, a compromised COMT activity may lead to accumulation of 
DOPEGAL, offering a very straightforward explanation to the pronociceptive effect of COMT 
inhibitors. However, some of the original results on DOPEGAL have been withdrawn, and the 
role of DOPEGAL in pronociceptive effects of low or absent COMT activity remains 
unconfirmed (Dina et al., 2009). 
 
Whereas the adrenergic mechanisms have been shown to mediate pronociceptive effects of 
COMT inhibitors, their role in mediating pronociceptive effects of an inborn COMT deficiency 
has not been verified experimentally (Nackley et al., 2007). In humans, ß-receptor blockers can 
reduce chronic musculoskeletal pain symptoms in patients carrying a low COMT activity 
haplotype (Tchivileva et al., 2010). Thus, adrenergic mechanisms seem to be involved also in 
pronociceptive effects of human COMT polymorphisms. 
 
BRAIN PENETRATION and site of action of COMT inhibitors. In earlier studies, 
nitecapone has been considered a peripherally acting compound, which does not cross the blood-
brain barrier (Männistö and Kaakkola, 1999; Nissinen et al., 1988). However, a high dose of 
nitecapone (30 mg/kg; i.p.) inhibited also striatal COMT activity, indicating that nitecapone can 
cross the blood-brain barrier to some extent, and therefore may exhibit direct effects in the brain 
(III). The inhibition of COMT in the brain is modest, lasting only for a short period of time 
(III), and its implications remain unclear. However, its effect on dopamine levels may be quite 
limited as dopamine levels in the striatum are not increased even in Comt knockout mice (Huotari 
et al., 2002). In the prefrontal cortex, however, the dopamine level is increased in the extracellular 
fluid when assessed with a no-net efflux method (Käenmäki et al., 2010). This increase may have 
functional consequences, since in Comt knockout mice the elimination time of prefrontal 
dopamine is doubled as shown by voltametric studies (Yavich et al., 2007). In line with Comt 
knockout studies, tolcapone, the COMT inhibitor which penetrates the blood-brain barrier, does 
not increase alone the rodent brain tissue or extracellular dopamine levels (Huotari et al., 1999; Li 
et al., 1998). However, after administration of L-dopa (Huotari et al., 1999, 2002), clozapine, or 
K+-hyperpolarisation (Tunbridge et al., 2004), tolcapone or complete COMT deficiency can 
increase dopamine levels. Thus, when COMT activity is seriously compromised, elimination of 
dopamine may be delayed, and there may be at least a shift towards an increased dopaminergic 
tone may occur in the brain. Therefore, it can be concluded that direct brain actions cannot be 
completely excluded from possible explanations of and may contribute to some extent to 
behavioural effects of nitecapone (II and III). Despite of that, COMT inhibition caused by 
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nitecapone in the periphery is significantly more pronounced and longer lasting, and thus may 
play a predominant role, rather than its effects in the brain. Nitecapone may also cross the blood-
cerebrospinal fluid barrier. However, since intrathecal administration of nitecapone did not 
increase nociceptive sensitivity (II), spinal action cannot explain pronociceptive effects of COMT 
inhibitors in models of acute pain. 
 
 
6.3 Effect of the pain type 
The effects of low COMT activity and COMT inhibitors on nociception seem to depend on the 
pain type. In acute and inflammatory pain, the effects are pronociceptive and sensitivity to 
nociceptive stimuli is increased. In neuropathic pain, however, pronociceptive effects are lacking 
in experimental animal models (III) (Jacobsen et al., 2010; Pertovaara et al., 2001) as well as in 
human polymorphism studies (Armero et al., 2005; Lötsch et al., 2009b; Max et al., 2006). In 
contrast COMT inhibitors have analgesic or antiallodynic effects (see in more detail below).  
 
 
6.4 Low COMT activity and efficacy of opioids 
 
6.4.1 Rodents 
 
Comt knockout mice showed enhanced response to morphine in the hot plate test (I). 
Enhancement of opioid response in polymorphisms with low COMT activity has also been 
reported in human studies in healthy volunteers and cancer pain patients (see below). 
 
We also found that in the tail flick test, which measures mainly spinal responses, a lack of COMT 
activity was related to loss of stress-induced analgesia and decreased morphine response. This 
indicates that COMT activity may be involved in the modulation of nociception and opioid 
responses not only in the brain, but also at spinal and/or peripheral levels. This can possibly 
occur via increased activation of Ƣ2/3-adrenergic receptors, as has been suggested in some other 
studies (Nackley et al., 2007) and was discussed in detail above. 
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6.4.2 Mechanisms 
 
It has been initially suggested that low COMT activity increases dopaminergic tone in certain 
brain areas, which in turn leads to a decrease in endogenous opioid peptides, and consequently to 
increased availability of opioid receptors (Zubieta et al., 2003). Our studies supported this 
hypothesis indirectly, since opioid analgesia was not modified by short-term administration of 
COMT inhibitors (Kambur and Männistö, 2009, unpublished results), but only after inborn COMT 
deficiency (I). This also suggests that enhanced morphine responses are not due to changes in 
catecholamine dynamics caused by inhibition of COMT directly, but rather due to compensatory 
changes in the level of protein synthesis, such as an increase in opioid receptor synthesis.  
However, the impact of changes in catecholamine dynamics on opioid analgesia cannot be 
completely excluded, as the pharmacological inhibition of COMT is not complete, especially in 
the CNS, whereas in the knockout mice COMT activity is completely absent and the relative 
magnitude of the effect on COMT activity is greater.  
 
OPIOID PEPTIDES. In situ-hybridization of opioid peptides in human post-mortem samples has 
not been unambiguous. In a more a recent study, the amount of proenkephalin mRNA was 
reduced only in the shell region of the nucleus accumbens (Nikoshkov et al., 2008), but in another 
study there were no reduction in the amount of preproenkephalin mRNA, in any brain region 
studied. In contrast, their amount was increased in the caudate nucleus (Berthele et al., 2005). In 
the thalamus, however, preproenkephalin was not detectable. Levels of Met-enkephalin peptide 
were within measurable range, and were decreased in the mediodorsal nucleus of the thalamus in 
Met-allele carriers (Kowarik et al., 2012). Ƣ-endorphin level neither was detectable neither in the 
thalamus nor in any other brain region studied (cortex, basal ganglia). Together these studies 
suggest that the endogenous opioid system is regulated by COMT polymorphisms, but is not in 
line with the initial hypothesis of Zubieta et al. (2003), which explains changes in opioid receptor 
availability by alterations in opioid peptide levels.  
 
OPIOID RECEPTORS. In human post mortem brain samples, genetic polymorphism 
(Val158/108Met) which is associated with a low COMT activity (Met-allele) was associated with an 
increased amount of opioid receptors in several brain areas: the caudate nucleus, nucleus 
accumbens and mediodorsal nucleus of the thalamus (Berthele et al., 2005). Increased level of μ-
opioid receptors in Met-allele carriers was later confirmed in mediodorsal nucleus of the thalamus 
in healthy volunteers (Kowarik et al., 2012). In the latter study the increase of μ-opioid receptors 
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in the thalamus was attributed to a decrease in Met-enkephalin level in the same area. Another 
opioid ligand, Ƣ-endorphin, was not detectable, and thus could not explain the observed changes. 
Indeed, the availability of μ-opioid receptors was increased in healthy volunteers with 
Val158/108Met polymorphism and low COMT activity in the anterior thalamus and thalamic 
pulvinar in in vivo imaging ([11C]carfentanil ligand-PET) study (Zubieta et al., 2003). Thus, 
regardless of the mechanism, COMT polymorphisms have been shown to regulate μ-opioid 
receptor availability, and a low COMT activity increases availability of opioid receptors in several 
brain regions. Together these findings indicate that COMT polymorphisms modulate opioid 
responses. 
 
6.4.3 COMT polymorphisms and postoperative opioid consumption 
 
Opioids are the most effective drugs in treating pain and remain widely used. The main factors 
limiting and attenuating their use are variation in efficacy, adverse effects, addiction, development 
of tolerance, and opioid-induced hyperalgesia. Consequently, they attenuate outcomes of pain 
treatment and compliance. There is convincing evidence from in vitro, ex vivo and in vivo animal 
studies, studies in human post mortem tissues, in vivo human imaging, that show regulation of 
opioid system by COMT.  COMT polymorphisms modulate not only the availability of opioid 
receptors, but also the effects of opioids, including their efficacy, adverse effects and opioid-
induced hyperalgesia. COMT polymorphisms and other genetic predictors of opioid effects may 
be used to optimize and improve treatment of pain patients, once patient genetic information is 
available to healthcare professionals.  However, there are several issues, which should be taken 
into account. Although the results of experimental studies have quite convincingly demonstrated 
changes in opioid system caused by COMT, the data showing effects of such changes on opioid 
treatment and outcomes in human patients are conflicting. Some of the clinical studies failed to 
show a significant effect (Huehne et al., 2009; Lötsch et al., 2009b), which  may have several 
explanations.  
 
1. Pain, opioid response, and requirements/consumption are complex multifactorial 
phenomena. Consequently, each of the contributing factors has a limited effect, and thus 
may explain only a fraction of the variation between individuals. It is not surprising that 
such effects can be seen more easily in experimental studies where the most confounding 
factors can be standardized and addressed. In a clinical setting, however, the effect 
(”signal”) of the same magnitude may be hidden by variation(”noise”) caused by 
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confounding factors, such as variation of pain symptoms, pathologies underlying the 
symptoms, stage of progression of the pathologies, clinical comorbidities, and other 
medications. In such cases, a low signal to noise-ratio in clinical studies and consequent 
lack of statistical significance of individual genetic factors do not diminish their relevance, 
but rather call for the other factors to be addressed – in clinical studies and in treatment of 
patients. 
 
2. Since COMT is not regulating opioid responses alone, the effects of other factors have to 
be taken into account. Opioid response is being regulated by genes coding for opioid 
receptors, and those regulating metabolic inactivation and pharmacokinetic parameters of 
the drugs. Whereas the effects of genes belonging to the latter category may depend on the 
particular opioid used, the analgesic effect of opioids is generally mediated via μ-opioid 
receptors which are coded by OPRM1-gene. OPRM1-gene is also subject for genetic 
polymorphisms, and it has been shown that the effect of COMT SNPs on opioid response 
may depend on an OPRM1-variant (A118G) (Reyes-Gibby et al., 2007). The effect of 
COMT SNP was most pronounced in carriers of AA variant, whereas in others it was less 
pronounced or not significant. Also another study pointed out the need to concomitantly 
address also other co-occurring genetic polymorphisms, which modulate the response and 
act as confounders (Lötsch et al., 2009a). 
 
3. Since COMT is proposed to regulate the opioidergic system via changes in dopaminergic 
tone in the CNS, also other factors regulating dopaminergic tone may modulate the effect 
of COMT on opioid responses. Polymorphisms in genes coding for dopamine receptors 
(DRD1-4), enzymes involved in biosynthesis and inactivation of dopamine (DBH, MAOB, 
DAT) and regulating other neurotransmitter systems (5-HT, NA) have been shown to 
modulate dopaminergic functions and phenotypes (Bertolino et al., 2008; Bobb et al., 2005; 
Bombin et al., 2008; Borroni et al., 2006; Xing et al., 2007). Also other genes modulate the 
dopaminergic system. For example, angiotensin I converting enzyme (ACE) regulates 
dopaminergic tone in the CNS and its gene has been shown to have an interaction with 
COMT (Illi et al., 2003; Jenkins et al., 1996; Mertens et al., 2010; Raghavendra et al., 1998; 
Reardon et al., 2000). Also DBH gene seems to be genetically linked with COMT, and/or 
may be regulated by the shared mechanisms (Xing et al., 2007).  
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4. Finally, the effect of an individual COMT SNP on complex responses such as opioid 
responses or pain, is ultimately dependent on its molecular mechanism of action. The 
effect of SNP is mediated via its physico-chemical interactions with other components of 
transcriptional and translational machinery in its immediate and more proximal 
environment. Thus, the effect is dependent on the location of the SNP within the gene and 
its interaction with other factors, such as other SNPs, binding sites for transcription 
factors, and other regulatory elements (see below).  
 
 
 
 
6.5 Mechanism of COMT inhibitors reducing the neuropathic 
pain 
 
6.5.1 Experimental rodent model of neuropathic pain 
 
At repeated doses once a day, nitecapone reduced symptoms of neuropathic pain induced by the 
SNL. Mechanical and cold allodynia were reduced when the treatment was started before or on 
the 2nd day after the induction of neuropathy. The antiallodynic effect of nitecapone was 
unexpected for two reasons: 1) it was opposite to pronociceptive effects seen in acute pain 
models, and 2) its duration of effect (over 24 hrs) exceeded manifold the duration of COMT 
inhibition (ca. 3 hrs) (III). Also other experimental studies on neuropathic pain have reported 
similar effects of COMT inhibitors (Jacobsen et al., 2010; Pertovaara et al., 2001). In a rat model 
of diabetes, nitecapone administered continuously in drinking water, decreased neuroplastic and 
nociceptive symptoms of neuropathy (Pertovaara et al., 2001). In another study, OR-486 (30 
mg/kg, i.v.) reduced spinal electrophysiological responses to nociceptive stimulation, and 
attenuated one of the neuroplastic changes underlying nociceptive sensitization in neuropathic 
pain, the spinal long-term potentiation (Jacobsen et al., 2010; Zimmermann, 2001). 
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6.5.2 Possible mechanisms 
The mechanisms underlying the antiallodynic effects of COMT inhibitors remain unknown. In 
diabetic neuropathy, nitecapone attenuated spontaneous activity of wide dynamic range neurons 
in the spinal dorsal horn offering a neurophysiological correlate to its antiallodynic effects 
(Pertovaara et al., 2001). Since OR-486 also modulated C-fibre responses in the dorsal horn and 
spinal long-term potentiation (Jacobsen et al., 2010), it seems obvious that COMT inhibitors 
directly or indirectly modulate spinal nociceptive transmission. 
 
ơ2. The noradrenergic stimulation caused by local administration of noradrenaline or ơ2-agonists 
produces antinociception (Danzebrink and Gebhart, 1990; Reddy and Yaksh, 1980). However, 
the antihyperalgetic effect of nitecapone in diabetic neuropathy was dependent neither on ơ2- 
adrenoceptors nor μ opioid receptors (Pertovaara et al., 2001). 
 
ơ1, D2. Also other catecholamine receptors in spinal cord may be involved in nociception. 
Activation of ơ1-adrenoceptors in the dorsal horn promotes antinociception (Baba et al., 2000). 
Additionally stimulation of spinal dopamine D2 receptors is antinociceptive (Liu et al., 1992; 
Munro, 2007; Pedersen et al., 2005).  
 
ß2/3. The adrenergic ß2-receptors are also expressed in the DRG, in peripheral tissues, and several 
parts of the brain (Nicholson et al., 2005). Initially, their role in antiallodynic effects in 
experimental neuropathy has been overlooked, as they were pronociceptive in models of acute 
pain (II) (Diatchenko et al., 2005; Nackley et al., 2007). Several recent studies, however, have 
shown that adrenergic ß2-agonists alleviate neuropathic pain via activation of adrenergic ß2-
receptors (Choucair-Jaafar et al., 2009; Yalcin et al., 2010), and that adrenergic ß2-agonism is 
necessary and sufficient for the antiallodynic effect of tricyclic antidepressants in animal models 
of neuropathic pain (Yalcin et al., 2009). Interestingly, blockade of ß2-adrenoreceptors blocked the 
effects of not only ß2-agonists but also of tricyclic antidepressants. These findings were further 
supported by a small case study in neuropathic pain patients (Cok et al., 2010). The mechanism of 
action of ß2-agonists in neuropathic pain is not known. ß2-agonists, however, decrease 
myeloperoxidase activity and lipid peroxidation, and increase the activity of superoxide dismutase 
and level of glutathione in inflammatory states (Elenkov et al., 2000; Uzkeser et al., 2012). They 
also modulate immune system responses for example by inhibiting tumor necrosis factor alpha 
(TNF-ơ) and interleukin 12 (IL-12) production. Thus, the effects of both, COMT inhibitors and 
ß2-agonists in neuropathic pain patients should be re-evaluated. Also, based on their mechanism 
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of action, COMT inhibitors are expected to have synergistic effect with tricyclic antidepressants. 
This should be explored in further studies as, in perspective, this could be utilized in treatment of 
neuropathic pain. Whereas the effect of ß3-agonism was not supported by the study of Yalcin et 
al. (2009), it could have an impact in some neuropathic pain states, such as diabetic neuropathy, 
as it seems to have disease modifying effects (Umekawa et al., 1997; Kiso et al., 1999; Weyer et al., 
1999). 
 
ANTIOXIDATIVE EFFECTS. Antiallodynic effect of nitecapone in neuropathic pain model 
may be at least partially explained by its pharmacological actions other than the short-term 
inhibition of COMT. Nitecapone is a potent antioxidant and it scavenges reactive oxygen and 
nitric oxide radicals and prevents peroxidation of lipids at clinically relevant concentrations 
(Männistö and Kaakkola, 1999; Marcocci et al., 1994a,b; Nissinen et al., 1995; Suzuki et al., 1992). 
Also, OR-486 may exhibit antioxidative properties to some extent. Oxidative stress plays an 
important role in neuropathic and other persistent pain conditions (Kim et al., 2004b; Salvemini et 
al., 1999; Tal, 1996; Wang et al., 2004). In animal models of neuropathic pain, free radical 
scavengers have reduced phosphorylation of NMDA-receptors, central sensitization, allodynia 
and hyperalgesia (Gao et al., 2005; Kim et al., 2006c; Kim et al., 2004b). Thus, antioxidative 
properties of nitecapone and OR-486 may contribute to their antihyperalgesic and antiallodynic 
effects. The duration of antioxidative action of nitecapone has not been directly studied in 
animals but there are some studies showing, indirectly, a prolonged action of nitecapone. For 
example, the protective effect of nitecapone in gastric lesions in rats lasted longer than 6 hrs, and 
the concomitant stimulatory effect on the release of prostaglandin E2 was even 12 hrs or more 
(Aho and Lindén, 1992). 
 
 
6.5.3 Humans  
 
Unlike in some other types of pain, COMT polymorphisms have not increased incidence or 
intensity of the symptoms of neuropathic pain in any of the human studies, including in 
neuropathic pain patients (Armero et al., 2005; Lötsch et al., 2009b; Max et al., 2006). The effect of 
nitecapone in our study (III) was comparable to that of drugs used in treatment of neuropathic 
pain in human patients, such as tricyclic antidepressants or gabapentin (30 mg/kg) in the same 
model (Joshi et al., 2006; Leventhal et al., 2007; Urban et al., 2005). Since clinically used COMT 
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inhibitors are well tolerated, their possible antiallodynic effects should be explored in future 
studies in rodents and humans to assess their potential in treatment of neuropathic pain. 
 
 
6.6 COMT gene mutations and human pain 
 
In our study (IV), the effects of COMT variation on pain were assessed using SNPs and 
haplotypes. In the human genome, SNPs and other bases are not transmitted alone, but rather in 
blocks. Thus, alleles of individual SNPs are usually accompanied by certain alleles of other co-
transmitted SNPs which together form haplotypes. A prevalence of such sets of SNPs varies, and 
most common haplotypes cover the majority of population, whereas some are relatively rare or 
absent from certain populations. All SNPs that comprise a haplotype contribute to the DNA 
sequence of the gene, which determines its physico-chemical properties and interactions with 
enzymes and regulatory factors, including transcription factors and small RNAs. Moreover, the 
effects of SNPs are modulated by other SNPs and haplotypes, which form its functional 
environment. A co-occurrence of several SNPs within the single haplotype can also have effects 
that are not seen in individual SNPs. For example, several simultaneous SNPs can result in 
altered local stem-loop structures and more stable mRNA that slows down its processing, and 
consequently reduces the amount of translated protein (Nackley et al., 2006). Such functional 
haplotypes modulate COMT activity and affect nociception more than individual SNPs, and thus 
provide a greater explanatory value and better face validity (Diatchenko et al., 2005). Also in our 
study, an association of the haplotype with pain phenotypes was statistically significant, providing 
explanatory value equal to or greater than individual SNPs (IV). 
 
6.6.1 Genetic associations (IV) 
 
EXPERIMENTAL PAIN — HEAT and rs165774. In our study (IV) heat pain intensity 
(48°C) showed the strongest association with SNP rs165774. The subjects carrying the A-allele 
showed lower pain intensity than homozygous G-carriers. Also the haplotype containing this 
allele, TTACACA, showed association with heat pain. The level of statistical significance and 
magnitude of the effect (Ƣ) of haplotype and SNP analysis were virtually identical. As rs165774A 
was the only variant present in this haplotype exclusively, it would be plausible to assume that in 
both comparisons the signal is driven by rs165774A alone.  However, as all rs165774A carriers 
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carried also the TTACACA-haplotype, we cannot formally exclude the impact of haplotype-
specific effects. Rs165774A was also associated with decreased cold pain intensity (90s), but only 
associations with the heat pain sustained corrections for multiple comparisons. The effect of 
rs165774 on experimental pain has not been studied before. Rs165774 is located in the intronic 
region between exons 5 and 6, and is part of haploblock 2. Rs165774A leads to the expression of 
an alternatively spliced COMT isoform. This truncated isoform may be differentially expressed 
and more efficient in metabolizing noradrenaline, as suggested in a recent preliminary report 
associating it with temporomandibular dysfunction (Meloto et al., 2012). 
 
EXPERIMENTAL PAIN — COLD and rs887200. Regarding the cold pain phenotypes, the 
strongest association in our study was detected between a rare SNP, rs887200, and cold pain 
intensity. Homozygous minor allele (C) carriers were 22-23 % less sensitive to pain than the 
subjects with other genotypes. The magnitude of the effect of rs887200 in our study was greater 
than that of other COMT SNPs, including several SNPs which have shown associations in earlier 
studies. The patients having C/C genotype reported lower pain intensity ratings consistently 
across different time points. Rs887200C also showed trends toward decreased heat pain intensity 
and increased oxycodone requirements, which were not statistically significant, but were of 
considerable size and followed the predictions based on cold pain associations.  
 
Rs887200 is located within a region adjacent to 3´UTR, which has recently been shown to be the 
main determinant of COMT activity and related behavioural phenotypes in animals (Segall et al., 
2010). In the study, which utilised eQTL analysis of inbred mouse strains, the variant was caused 
by a transposon. In humans, rs887200 has not been studied in pain phenotypes before, and its 
effects on COMT activity are currently unknown. Other SNPs in the COMT 3´UTR-region have 
been linked to neuropsychiatric phenotypes (Stein et al., 2005; Shifman et al., 2002) and altered 
COMT expression (Bray et al., 2003). 3´UTR-variants do not directly alter the amino acid 
sequence of the protein, and therefore their mechanisms of action are less evident. Possible 
mechanisms include attenuation of interaction of the 3´UTR-area with negative modulators of 
expression such as microRNAs (Lewis et al., 2003) with a consequent increase in expression. The 
in silico eQTL searches we performed did not provide evidence of this SNP affecting COMT 
expression levels significantly in the cell types available. This, however, is logical, as 3´UTR 
modulators are small regulatory molecules, which may be synthesised in neighbouring cells or 
only in particular conditions and expected to be lacking from the cell culture. Rs887200 is also 
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intragenic to a neighbouring gene, ARVCF, which codes for the armadillo repeat protein deleted 
in the velocardiofacial syndrome, but its impact seems rather unlikely. 
 
Interestingly, rs887200 showed significant interaction with CCG (HPS)-haplotype, suggesting 
that they both may contribute to the decreased pain intensity. This interaction provides an 
explanation to the surprising results of HPS/HPS-haplotype and shows that rs887200 may act as 
a confounder masking other more moderate effects of LPS/APS/HPS-haplotypes. 
 
SNPs and haplotypes of the 2nd haploblock. Clinical postoperative pain was associated with 
SNPs rs4646312, rs2239393, and rs4818 in the SNP and haplotype analyses, whereas rs4680 did 
not reach the level of statistical significance (p=0.1)( Appendix 1: Tables 6 and 8)(IV). In the 
SNP analysis, the carriers of the more rare alleles of these SNPs (rs4646312C, rs2239393G and 
rs4818G) reported higher postoperative pain scores at rest (uncorrected p=0.006-0.007) and 
during motion (uncorrected p=0.009-0.01) at the time when they needed the first dose of 
oxycodone, than the patients being homozygous for the major allele. Also in analysis of 
LPS/APS/HPS-haplotypes, which are defined by the SNPs rs4633, rs4818 and rs4680, CGG 
(LPS)-haplotype, containing minor alleles of rs4646312, rs2239393, and rs4818 was associated 
with increased postoperative pain ratings (rest pain, p=0.008, Ƣ=0.251; motion pain, p=0.011, 
Ƣ=0.241). The effect sustained multiple comparison corrections (rest pain, p=0.02).  
 
One interpretation to this is that carriers of minor alleles tolerate more intense pain before 
requesting analgesic. However, in other phenotypes, the time of administration of the first 
oxycodone dose did not differ between the genotypes, which does not support this 
interpretation. SNPs rs4646312C and rs4818G showed a tendency towards higher pain ratings 
upon awakening (Appendix 1: Table 6). Rs4818G was also associated with increased cold pain 
intensity and decreased cold pain tolerance. Consistently, CGG (LPS)-haplotype increased the 
intensity of cold pain and decreased cold pain tolerance and CCG (HPS)-haplotype showed an 
opposite effect, which sustained corrections for multiple comparisons (p=0.009). In the earlier 
studies, however, LPS-haplotype and its marker SNP rs4818G have been associated with 
decreased postoperative and experimental pain intensity (Diatchenko et al., 2006; George et al., 
2008b; Lee et al., 2011). One study assessing rs4818, however, failed to confirm this (Kim et al., 
2006a). At first glance, both associations were equally surprising as they were opposite to the 
prediction of earlier pain studies in other pain phenotypes, which were supported by COMT 
activity experiments. The effects seen in our study, however, were most pronounced in the 
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recessive model. A recessive model compares homozygous carriers to the rest of the population, 
and presumes a recessive genotype effect, which is carried primarily by homozygotes (Lewis, 
2002). HPS/HPS represents a relatively rare haplotype (n=18 in cold pain phenotypes), which 
was lacking, excluded, or extremely scarce in studies by Diatchenko et al. (2005, 2006) and other 
earlier studies. Thus, predictions regarding the HPS-haplotype were based on heterozygotes, 
omitting homozygote data and thus lacking sufficient predictive potential regarding HPS/HPS 
carriers. Nevertheless, among haplotypes introduced by Diatchenko et al. (2005, 2006), HPS 
haplotype has been predicted to be more sensitive to pain and to have lower COMT activity 
compared to other haplotypes. Thus it could be presumed, that these effects would be most 
pronounced in HPS/HPS carriers. However, such extreme variants can be accompanied by other 
mutations, which can compensate for insufficient COMT activity and, consequently, their 
phenotype effects (see below). We hypothesized that such compensatory variants would explain 
exceptional effects of LPS/LPS and HPS/HPS haplotypes on pain phenotypes.  
 
On a general level, such compensatory mutations could act like rare variants, which have been 
shown to modulate the effect of common COMT variants, and act like confounding factors 
(Lötsch et al., 2009a). In our study, the best candidates with potential to act as protective variants 
and confound the detrimental effect of the HPS allele in homozygous carriers, were rs887200 and 
possibly rs165774.  Indeed, the analysis of epistatic interactions confirmed that there was an 
interaction between rs887200 and HPS-haplotype and in all cases the HPS/HPS haplotype was 
accompanied by the C/C-variant of rs887200, both contributing to the decreased pain intensity 
in the cold pain test. Rs887200 also showed interaction with APS (TCA)-haplotype, which 
decreased cold pain intensity. The magnitude of the effect was smaller (Ƣ=-0.59 vs.-0.97) 
apparently due to the fact that in the most of the patients APS-haplotype was accompanied by a 
single rs887200C-allele whereas HPS/HPS carriers had two of them. 
 
As to LPS/LPS haplotype effects, they are to significant extent contributed by HPS/HPS and 
APS haplotype, which were included in the control group to which LPS/LPS haplotype carriers 
were compared. LPS/LPS carriers also mostly lacked the protective effect of rs887200C-allele, as 
95% of LPS/LPS-carriers were rs887200T-homozygotes thus lacking even an individual C-allele. 
Additionally, Bray et al. (2003) showed that SNP rs737865 and rs165599 variants can modulate 
allelic expression of COMT mRNA in certain haplotypes, including rs4633C, via cis–acting 
mechanisms. Rs737865 and other SNPs and haplotypes of the 1st block may possibly modulate 
the effects of LPS/APS/HPS-haplotypes on pain phenotypes, since they have been associated 
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with cold pain phenotypes (uncorrected p<0.05), and their effect on COMT mRNA expression 
has been shown in human tissues.  
 
Taken together, it seems that the effects of functional COMT haplotypes of the 2nd haploblock on 
pain phenotypes may be modulated by 3´ and 5´UTR SNPs showing rather complex interactions 
on molecular and/or phenotypic level. This is in line with earlier in vitro and ex vivo studies, which 
have shown genetic interactions between these variants (Bray et al., 2003) and their importance in 
neuropsychiatric phenotypes (Shifman et al., 2002;  Hatzimanolis et al., 2013).  Impact of different 
COMT variants and their interactions remains to be verified and analysed in-depth in future 
studies. Linear regression analysis assumes that the effects of different genotypes are 
independent, and therefore does not allow reliable evaluation of such interactions. Thus, 
alternative analysis methods such as epistatic interaction analysis or multivariate regression 
analysis should be used in future studies to characterize such interactions. Moreover, statistical 
methods based on the assumption of independent effects, such as Bonferroni correction for 
multiple comparisons, are overconservative for assessing the effects of different COMT variants. 
Therefore, interactions between different variants and over conservativeness of Bonferroni 
corrections should be taken into account when interpreting earlier studies assessing multiple 
COMT variants. 
 
6.6.2 Haplotypes and haploblocks (IV) 
 
2nd HAPLOBLOCK. Among the detected haplotypes, the most interesting were those in the 
2nd haploblock. TTACACA,  the only haplotype containing a minor allele of rs165774 (A), has a 
frequency of 24% and was associated with decreased heat pain intensity (uncorrected p=0.003, 
Ƣ=-0.463). In contrast, CCGGGTG, a haplotype containing a major allele (G), showed 
association with increased cold pain intensity after 30 and 45 s and decreased cold withdrawal 
time.  
 
THE 3rd HAPLOBLOCK - experimental cold and rs887200 haplotypes. As rs887200 
showed the best association with cold pain, the haplotypes containing its minor allele were of 
special interest. Within the 3rd haploblock two haplotypes had this allele. Neither CGATC, nor 
CGAGC reached the level of statistical significance. This can be explained by the fact that the 
main effect of rs887200 was seen in homozygous carriers which all represented CGATC-
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CGAGC-diplotype. As homozygous carriers were lacking from both haplotypes, diplotype 
carriers were pooled together with other heterozygous carriers and the effect of diplotype was 
diluted. Finally, heterozygous carriers were compared against each other as CGATC-carriers were 
included in control group of CGAGC-haplotype and vice versa. 
 
CLINICAL PAIN. In clinical pain, most significant associations were observed between the 
CGG-haplotype and increased intensity of postoperative pain (IV). CGG is present in 
CCGGGCG and CCGGGTG haplotypes which, however, showed only a trend lacking statistical 
significance. The lack of significance may mainly be due to the distribution of these variants into 
two haplotypes, thus contributing to increased postoperative pain scores in both of them. 
Consequently in the comparison of each haplotype, another haplotype containing CGG was 
included in the control group thus leading to lack of association signal. These results suggest that 
association signal may be primarily due to either individual SNPs or the CGG-haplotype, whereas 
possible modulatory effects of other SNPs in the 2nd haploblock remain to be studied by further 
diplotype and interaction analyses.  
 
METHODOLOGICAL DISCUSSION. There are several issues that need to be taken into 
account when interpreting the results of Study IV. Firstly, approximately 25% of the breast 
cancer patients we studied had some previous chronic pain condition. LPS/APS/HPS haplotypes 
were associated with the prevalence of reported chronic pain. In LPS/LPS carriers the prevalence 
was 18.9%, while in HPS/HPS-carriers it was 35%. Thus, when we adjusted for earlier chronic 
pain conditions, we also corrected the effect of the haplotype. Secondly, it must be noted that 
follicular phase or post menopause were not addressed. It is known that COMT is downregulated 
by estrogen, and therefore its possible confounding effects cannot be excluded. Further studies 
are necessary to understand the interaction of such confounding factors with COMT genotypes 
and pain.     
 
In clinical pain phenotypes there were less association signals and they were less significant 
compared to experimental pain, which might be due to several reasons. The data from clinical 
pain phenotypes was missing from some of the patients (n=20-70). For example, pain intensity 
was asked specifically when oxycodone was requested. However, it was not needed by some of 
the patients, and therefore pain intensity was not recorded. Also, the day-case surgery patients 
with likely milder symptoms were excluded from the analysis of oxycodone phenotypes. Thus, 
patients with presumably low pain intensity were excluded from postoperative pain intensity and 
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oxycodone data. This may represent a potential bias, since  these patients were more prevalent  in 
certain genotypes, including the rare variant rs887200-CC. These factors might affect the results 
of the haplotype analysis but also the analysis of individual SNPs.   
 
In general, the data from postoperative phenotypes is more variable than experimental phenotype 
data. Although we adjusted for a number of confounders including the type of surgery, the extent 
of tissue damage, and duration of the operation, pre- and perioperative medication varied from 
patient to patient. Also, whilst the origin of experimental pain is clear, postoperative pain is likely 
to represent mixed pain, which contains not only inflammatory pain, but also a neuropathic 
component, as nerve fibers have been damaged to varying extent in virtually all of the patients. 
The impact of neuropathic component is particularly challenging to estimate, as in neuropathic 
pain low COMT activity is supposed to have opposite effects as compared with nociceptive pain. 
Finally, the impact of cognitive and emotional processes after a major surgery is greater, since the 
sense of security and controllability, typical to experimental pain tests, is lacking.  
 
6.6.3 Phenotype-specific effects 
 
A central question is why do the effects of different COMT SNPs appear, at least to some extent, 
be phenotype specific, if they act via changes in COMT activity via a common mechanism? This 
was observed in studies assessing rs4680 and haplotypes – within the same study rs4680 was 
associated with temporal summation of pain and haplotypes were associated with other pain 
phenotypes (Diatchenko et al., 2006). Also in other studies rs4680 has been associated with pain 
responses if stimulation has been of higher intensity and of prolonged duration (Jensen et al., 
2009; Loggia et al., 2011; Zubieta et al., 2003).  In our study, a different set of SNPs gave an 
association signal in cold and heat pain. 
 
It must be kept in mind that in different pain phenotypes the extent of involvement of CNS-
processes is different. If the stimulus is short, applied to a small area, and the intensity is relatively 
low, the involvement of CNS-processes is minimal. As intensity and duration of pain stimuli, and 
the area of stimulation increase, CNS-processes and endogenous pain modulation become more 
involved and contribute to the final pain experience to a greater extent. If the phenotype includes 
tolerance to pain (as in cold pressor task), the impact of CNS is even greater.  
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COMT has been shown to increase nociceptive sensitivity via peripheral mechanisms (II) but 
also in CNS where it modulates pain processing and expression of endogenous opioids and 
opioid receptors (Berthele et al., 2005; Kowarik et al., 2012; Loggia et al., 2011; Mobascher et al., 
2010; Nikoshkov et al., 2008; Zubieta et al., 2003). The first effect has been shown to be 
mediated via adrenergic Ƣ-receptors and involves adrenergic or noradrenergic neurotransmission, 
and the latter effect has been attributed to the involvement of dopaminergic and endogenous 
opioid systems in prefrontal cortex and other brain areas processing nociception (Nackley et al., 
2007; Zubieta et al., 2003). Genetic determinants of these two effects are partially overlapping. In 
the periphery, a major part of COMT activity is due to S-COMT, whereas in the brain, MB-
COMT is the predominant isoform. Thus, SNPs specific to MB-COMT, such as rs737865 
located in the first MB-COMT-intron, could modulate CNS-processing of pain while lacking 
peripheral effects (Bray et al., 2003). SNPs located in the region coding for S-COMT, such as 
rs4818 and rs4633 (Diatchenko et al., 2005, 2006; Tsao et al., 2011) are also present in MB-COMT 
and thus could modulate both, the peripheral and CNS-effects. In the CNS, however, their 
effects may be modulated by MB-COMT-specific SNPs such as rs737865, which modulate the 
expression of rs4633-variants, and rs737865C relatively decreases expression of rs4633C-
rs4680G-variant (Bray et al., 2003). 
 
In addition to these mechanisms, there may also be a longer transcript, which extends over 
conventional polyadenylation site at the 3´end, and covers rs165599 (Bray et al., 2003) and a 
truncated variant caused by rs165773 (Meloto et al., 2011). Both variants decrease expression of 
COMT. A variant containing rs165599 has been identified in the brain and may be more 
important in the modulation of CNS-processes, as it also has been associated with 
neuropsychiatric phenotypes. SNP rs165773 and the truncated variants may be more important 
in the periphery, as they are more efficient than non-truncated S- and MB-COMT in 
metabolizing noradrenaline, which is the main component of peripheral effects of low COMT 
activity. In the CNS, however, its effects may be opposite, since it reduces COMT expression 
decreasing COMT activity involved in dopaminergic CNS-processing. Thus, rs165773 and to 
some extent rs165599 show substrate specific effects.  
 
SUBSTRATES. Differential effects on level of different COMT substrates could result in 
phenotype specific effects. If a SNP is modulating effects of noradrenaline or adrenaline, which 
are mediated via adrenergic Ƣ2/3 receptors, its effects would be mainly seen in phenotypes in 
which peripheral catecholamines play a more important role, such as in pain sensitivity or 
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intensity after a brief stimulation. In contrast, the SNPs modulating dopaminergic transmission in 
CNS, such as rs4680, and consequently compensatory systems could have more pronounced 
effects in phenotypes in which CNS or targeted neural circuits are important. These include 
temporal pain summation after repetitive stimulation, pain intensity after prolonged stimulation, 
or opioid responses. It must be also noted that whereas the effects of haplotypes described by 
Diatchenko (2005, 2006), Nackley (2006) and Tsao (2011) have a strong peripheral component, 
the effects on CNS-processing have mostly been shown with rs4680 (Val108/158Met) (Loggia et al., 
2011; Mobascher et al., 2010; Zubieta et al., 2003). 
 
TISSUE and “STATE” SPECIFITY.  COMT variants may interact with systems regulating 
tissue- or “state” specific expression of COMT. In these cases, effects of such SNPs would be 
more pronounced in phenotypes that involve nociceptive processing in these tissues, or in 
corresponding pathophysiological states. Interaction of SNP with tissue and “state” specific 
mechanisms could provide another hypothetical explanation for the observed phenotype-specific 
effects of COMT SNPs.  
 
COMBINATORIAL EFFECTS. From a molecular perspective, several genetic factors 
contribute to COMT expression, structure, or activity. SNP rs4680 (Val108/158Met) modulates 
thermostability of COMT and consequently COMT activity, and the Met-variant has decreased 
stability (Lotta et al., 1995). In Val-allele carriers, COMT activity is additionally modulated by 
rs4818 (Nackley et al., 2006), which contributes to the expression of COMT. G-allele present in 
LPS-haplotype is associated with higher COMT expression and C-allele in HPS-haplotype with 
reduced COMT expression, at least in some tissues. Furthermore, in Val-carriers expression of 
COMT is modulated by rs737865 of the first MB-COMT-intron (Bray et al., 2003). Rs737865C 
decreases relative expression of rs4633C-rs4680G-variant, as has been shown in the brain tissue. 
In Met-allele carriers, COMT activity is also modulated by rs4633. Rs4633T, which is present in 
APS haplotype increases expression of COMT, thus compensating for decreased stability of Met-
variant at least in some tissues in a tissue-specific manner (Tsao et al., 2011). It is also not clear if 
relative decrease in allelic expression of rs4633C-variant by rs737865C can increase the relative 
expression of rs4633T-variant. Part of Met-carriers, however, also carries rs165773A and an 
alternatively spliced COMT variant, which causes decreased expression but is more efficient in 
metabolizing noradrenaline (Meloto et al., 2011). Finally, rs165599 located in the 3´UTR area can 
decrease expression of COMT at least in the brain (Bray et al., 2003). This effect can be due to the 
alternatively spliced longer COMT isoform as rs165599 is located 3´ from the conventional 
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polyadenylation site, and variants containing it have been detected in the brain (Bray et al., 2003). 
We hypothesized that also rs887200C increases COMT expression, which is likely caused by an 
attenuated interaction with negative regulatory factors and prevention of negative modulation. 
However, other mechanisms cannot be totally excluded. For example, as Bray et al. (2003) 
showed, also other, longer COMT transcripts, may exist, and such alternatively spliced variants 
could offer an alternative explanation to the effects of rs887200C. 
 
Thus, several polymorphisms modulate COMT expression and/or activity. The net effect on 
COMT activity in each subject may not be due to the effects of individual SNPs, but rather a 
result of a particular combination of these variants and their interactions. Different SNPs or their 
combinations may act via different/multiple mechanisms in additive, synergistic or antagonistic 
manner. Each individual also has two variants of COMT, which may differ in their structure and 
function, thus adding to the complexity of effects of COMT variants.  
 
CONFOUNDING FACTORS and “observed” phenotype specific effects of COMT.  
Finally, part of the observed phenotype specific effects of COMT variants may reflect 
methodological study- or phenotype-specific issues, rather than real phenotype-specificity. 
Studies comparing effects of different COMT variants are scarce and differ in their pain 
phenotypes as well as in the subjects studied. Thus, positive correlation of particular variants in 
one study and absence of effects in other study may be due to methodological differences.  On 
the other hand, differences between phenotypes within the same study may arise from 
phenotype-specific  factors, such as different inherent variation of the responses, scales of the 
used phenotypes, and size or magnitude of the overall effects. 
 
 
6.6.4 Putative mechanisms of COMT variants 
 
PUTATIVE MECHANIMS of ACTION of COMT SNPs. Whereas several SNPs within 
COMT gene have shown significant associations with clinical and experimental pain phenotypes, 
susceptibility to develop chronic pain condition or, with experimental or clinical pain intensity, 
the mechanism underlying these effects is not known. It seems likely that the effects are caused 
by changes in COMT function, such as decreased activity. Such change has been shown in SNP 
rs4680 (Val108/158Met), which causes a change in the amino acid sequence of COMT from valine 
to methionine, increasing the thermolability of the protein and decreasing COMT activity in vivo. 
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The effects of vast majority of other SNPs within COMT gene on COMT activity and resulting 
nociceptive phenotype remain unknown. Practically all the other SNPs in COMT that have been 
studied in relation to pain are either synonymous, and do not change the amino acid sequence of 
the protein, or are located in introns. However, it cannot be excluded that the effect of the 
synonymous SNP on phenotype is in fact caused by another, coding or non-synonymous SNP 
that is tightly linked to it. However, this possibility seems rather theoretical.  
 
Non-synonymous SNPs cause an exchange of amino acids, and nonsense SNPs can result in a 
premature stop codon, and thus their effect on the coded protein is evident. However, also 
synonymous and SNPs located within 5´- and 3´-UTRs, UTR-adjacent areas, and intronic and 
intergenic regions can be associated with different diseases. It has been estimated that only 8.7 % 
of SNPs associated with diseases are non-synonymous.  In fact, synonymous and non-
synonymous SNPs are as likely to be associated with the diseases as non-synonymous, and their 
effect sizes are similar (Chen et al., 2010).  
 
INTRONIC SNPs. In general, 52% of disease-associated SNPs are located in intronic regions. 
SNPs within the first intron are more likely to be associated with diseases than those in other 
introns. Especially SNPs located in the proximity of the 80th base from the beginning of the first 
intron seem to be more likely associated with diseases (0.85% probability vs. 0.5 %) (Chen et al., 
2010). 
 
SNPs and mRNA. It has been shown that COMT haplotypes alter the secondary structure of 
mRNA modulating protein expression (Nackley et al., 2006). SNPs, however, do not necessarily 
decrease expression of COMT gene or decrease COMT activity. Some of the SNPs, such as 
synonymous rs4633 (C166T), located in 5´UTR of the RNA transcript, can increase the expression 
of COMT in vitro, which was explained by structural destabilization of mRNA, and consequent 
increase in translational efficiency (Tsao et al., 2011). Since this mutation is usually present as part 
of a common haplotype with low or unstable COMT activity, it has been suggested to be a 
compensatory genetic change. 
 
3´UTR. SNPs in the 3´UTR are as frequently associated with diseases as non-synonymous SNPs. 
SNPs in 3´UTR, and possibly in 5´UTR, may interfere with interaction between DNA and 
regulatory elements, such as microRNAs, and their role is underinvestigated. In our study (IV), 
SNP rs887200, which was associated with different pain phenotypes, is located in such an 
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untranslated region. The protective effect observed in homozygous carriers of rs887200C could 
be explained by an attenuated interaction with negative regulatory factors and a consequent 
prevention of negative modulation. In general, the effect of a SNP is due to its effect on physico-
chemical properties of DNA, or resulting mRNA, and a consequent alteration of its interaction 
with other factors. Such factors include DNA- or RNA-processing enzymes, transcription 
factors, small RNAs and other cis- and trans-acting regulatory elements.  
 
REGULATORY SITES. COMT gene contains several regulatory sites. Many of them are 
located within P1 and P2 promoter regions that contain binding sites for different transcription 
factors, such as AP-2, Ets-1, Sp1, and NF-D within the P2 coding for a longer transcript, and 
binding sites for factors HNF-4, Sp1, AP-2 and NF-IL6 in P1 coding for a shorter transcript. P1 
also contains a binding site for C/EBPa that regulates tissue-specific expression of COMT 
(Tenhunen, 1996). Also, 3´UTR and possibly 5´UTR contain binding sites for regulatory factors. 
If a SNP is located within or in the vicinity of a binding site of a regulatory factor, it can 
modulate its function. Consequently, its own effect can depend on the presence or absence of a 
regulatory factor. For example, if a SNP would prevent the binding of a regulatory factor, its 
effect could be seen when the factor is present, resulting in a change in transcription, whereas 
when the factor is absent and the regulatory site is functionally silent the SNP would show no 
effect. 
 
For example, a mutation in the estrogen-regulatory site providing negative regulation of COMT 
expression, could prevent such negative regulation, and its effect on protein expression and 
consequent clinical or physiological phenotypes would be greater during the phases of menstrual 
cycle when  estrogen level is increased. COMT contains a regulatory site for another sex 
hormone, progesterone, as well. Regulation of COMT is also dependent on factors controlling 
tissue-specificity, such as C/EBPa (Tenhunen, 1996). Both tissue- and hormone specific 
regulation of COMT are clinically interesting, since they can help to narrow down and specify the 
group of patients or pain states in which certain SNPs would be important. For example, a SNP 
affecting estrogen-mediated regulation of COMT could be important in females, and its effects 
could be more important during the phases with high estrogen level and in tissues with a higher 
estrogen receptor density (for example vulvodynia, premenstrual syndrome or hormone-
dependent cancer). In males, however, the same SNP would not have similar predictive value.  
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MicroRNA. COMT contains several microRNA binding sites (Table 9), and these microRNAs 
regulate gene functions. Their role has been shown in endothelial aging and inflammation (Qin et 
al., 2012), regulation of cell stress and proliferation processes (Staszel et al., 2011), cell death, 
epigenetic regulation, diabetic and other neuropathies, as well as in cancer and Huntington’s 
disease.  
 
GENE-GENE and OTHER INTERACTIONS. COMT is also regulated by other genes and 
by several physiological states, such as trauma, stroke, and inflammation.  Both types of 
interactions are dependent on regulatory sites within the COMT gene. Such regulatory sites may 
contain different SNPs, which contribute to the genetic effect. Genes that interact with COMT 
include those coding for ACE (mediated via P21964, P12821), lipopolysaccharide-induced TNF 
factor (LITAF, mediated via P21964, Q99732), thyroid hormone receptor interactor (TRIP13), 
mediated by two different mechanisms (P21964, Q15645 and BioGRID:107707, 
BioGRID:114730) and 5'-3' exoribonuclease 2 (XRN2) mediated by two mechanisms, 
(P21964,Q9H0D6 and BioGRID:107707, BioGRID:116483). Others include a PCNA-associated 
factor (KIAA0101), regulator of G-protein signalling 2 (RGS2), ubiquitin C (UBC), valosin 
containing protein (VCP), and vitamin K epoxide reductase complex, subunit 1 
(VKORC1)(Emanuele et al., 2011; Illi et al., 2003; Kim et al., 2011; Lehner and Sanderson, 2004; 
Rual et al., 2005; Schaafhausen et al., 2011; Stelzl et al., 2005; Vinayagam et al., 2011; Yu et al., 
2013). Especially interactions with ACE and LITAF genes are interesting. ACE and COMT have 
potential interactions with the vascular system and pain states such as migraine in which it plays 
an important role. ACE is also involved in processing of vasoactive and other peptides and 
endothelial function. Interestingly, the use of ACE-inhibitors has been linked to CRPS and 
inflammatory pain (Fein et al., 2009; de Mos et al., 2009). On the other hand, interaction of 
COMT with ACE and the cardiovascular system may explain some aspects of interactions of 
blood pressure and pain and Ƣ-receptor mediated pronociceptive effects of low COMT activity. 
LITAF and TNF-ơ could link COMT to the immune system, nociceptive chemokines, 5-
lipoxygenase and cyclooxygenase-2 pathways, and inflammatory pain.  
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7 CONCLUSIONS 
 
Low COMT activity was shown to be pronociceptive in experimental animal models of acute and 
inflammatory pain, whereas COMT inhibitors were antinociceptive in a neuropathic pain model. 
In humans, pain phenotypes were modulated by several SNPs.   
 
1. COMT deficiency in Comt knockout mice was associated with an enhanced response to  
morphine in the hot plate test, which is in line with the human studies showing increased 
availability of opioid receptors and enhanced morphine response in polymorphisms with low 
COMT activity. Comt knockout mice also showed decreased stress-induced analgesia in the tail 
flick test, suggesting weaker endogenous modulation of nociception on spinal/peripheral level. In 
the tail flick test, also opioid-induced antinociception was decreased, suggesting spinal and/or 
peripheral pronociceptive or antianalgetic effects of COMT deficiency.  
 
2. Pronociceptive effects of several types of COMT inhibitors were confirmed in normal  
mice, and shown to be mediated primarily via mechanisms acting outside the CNS in COMT-
dependent manner. COMT inhibitors increased both thermal and mechanical nociception, and 
increased inflammatory pain resulting from the pronociceptive effect of carrageenan in an 
additive rather than synergistic manner. Pronociceptive effects seemed to be mediated via 
peripheral mechanisms, as they were neither dependent on brain penetration of COMT inhibitors 
nor seen after intrathecal administration of nitecapone. Since a lack of Comt gene abolished 
further pronociceptive effects of OR-486, the effects are likely COMT-mediated. This was 
indirectly supported by the pronociceptive effect of an atypical COMT inhibitor CGP 28014.  
 
3. In an experimental SNL model of neuropathic pain, a COMT inhibitor nitecapone  
partially prevented or reversed neuropathic pain symptoms, cold and mechanical allodynia, and 
hyperalgesia. Our results show that in contrast to the pronociceptive effects observed in acute 
and inflammatory pain models, in neuropathic pain, the effects of nitecapone are antiallodynic, 
antihyperalgesic or antinociceptive.   
 
4. Pain phenotypes were modulated by several COMT SNPs in our cohort of 1000 breast  
cancer surgery patients. The effects were the most pronounced in two novel SNPs, the effects of 
which were described for the first time. Effects of these mutations on COMT activity are not 
known, but they are likely to represent novel mechanism of action.  
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APPENDIX 1: TABLES 4-9 
 
 
Table 4. Associations of COMT single nucleotide polymorphisms with intensity of thermal pain 
in breast cancer surgery patients (n=1000). 
 
 
Table 5. Association between COMT SNPs and experimental cold pain in patients undergoing 
breast cancer surgery (n=900). 
 
 
Table 6. Association of COMT SNPs with postoperative pain and oxycodone consumption. 
 
 
Table 7. Association between COMT haplotypes and experimental pain in patients undergoing 
breast cancer surgery (n=900).  
 
 
Table 8. Associations of COMT haplotypes with intensity of acute postoperative pain and i.v. 
oxycodone consumption in breast cancer surgery patients (n=1000). 
 
 
Table 9. Predicted microRNA binding sites in COMT gene. 
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APPENDIX 2: ORIGINAL PUBLICATIONS I-IV 
 
 
I  Stress-induced analgesia and morphine responses are changed in catechol-O-
methyltransferase-deficient male mice. 
 
 
II  Inhibitors of catechol-O-methyltransferase sensitize mice to pain. 
 
 
III  Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve 
ligation in rats. 
 
 
IV  Effect of COMT-gene variants on experimental and acute post-operative pain in humans. 
 
 
 
